[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10085
1. Tobinai K: Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park); 2009 Dec;23(14):1250-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of adult T-cell leukemia/lymphoma.
  • When oncologists diagnose patients suspected of lymphoid malignancy, it is important to consider the possibility of adult T-cell leukemia/lymphoma (ATL) with a routine check for serum human T-cell lymphotropic virus type 1 (HTLV-1) antibody.
  • (1) cytologically or histologically proven peripheral T-cell malignancy, and (2) positivity for anti-HTLV-1 antibody.
  • For patients with the acute or lymphoma type requiring therapy, enrollment in a clinical trial is recommended.
  • Because most patients with ATL are not curable with current chemotherapy regimens, it is reasonable to consider the applicability of allogeneic stem cell transplantation inpatients who show responses to chemotherapy.
  • For relapsed or refractory patients, enrollment in a new-agent trial should be considered in addition to stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Deltaretrovirus Antibodies / blood. Female. Hematopoietic Stem Cell Transplantation. Humans. Kaplan-Meier Estimate. Male. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2009 Dec;23(14):1267, 1270 [20120839.001]
  • [CommentIn] Oncology (Williston Park). 2009 Dec;23(14):1256, 1261, 1266 [20120838.001]
  • (PMID = 20120837.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Deltaretrovirus Antibodies
  •  go-up   go-down


2. Nomura K, Utsunomiya A, Furushou H, Tara M, Hazeki M, Tokunaga M, Uozumi K, Hanada S, Yashiki S, Tajima K, Sonoda S: A family predisposition to adult T-cell leukemia. J Clin Exp Hematop; 2006 Nov;46(2):67-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A family predisposition to adult T-cell leukemia.
  • We report here the rare case of a family predisposed to adult T-cell leukemia (ATL).
  • [MeSH-major] Genetic Predisposition to Disease. HLA-A Antigens / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17142956.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / HLA-A Antigens
  •  go-up   go-down


3. Jeang KT: HTLV-1 and adult T-cell leukemia: insights into viral transformation of cells 30 years after virus discovery. J Formos Med Assoc; 2010 Oct;109(10):688-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 and adult T-cell leukemia: insights into viral transformation of cells 30 years after virus discovery.
  • Human T-cell leukemia virus type 1 (HTLV-1), the etiological agent of adult T-cell leukemia, was the first human retrovirus to be isolated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Formosan Medical Association & Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20970064.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Gene Products, tax; 0 / PDRG1 protein, human; 0 / Tumor Suppressor Protein p53; 0 / tax protein, Human T-lymphotrophic virus 1
  •  go-up   go-down


Advertisement
4. Khadilkar UN, Mathai AM, Chakrapani M, Prasad K: Rare association of papillary carcinoma of thyroid with adult T-cell lymphoma/leukemia. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):125-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare association of papillary carcinoma of thyroid with adult T-cell lymphoma/leukemia.
  • We report a rare association of papillary carcinoma of thyroid in an elderly lady with adult T-cell lymphoma/leukemia.
  • Fine needle aspiration of the thyroid, neck nodes and evaluation of the bone marrow and peripheral blood helped in the diagnosis of papillary cancer coexisting with adult T-cell lymphoma/leukemia.
  • [MeSH-major] Carcinoma, Papillary / complications. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Thyroid Gland / pathology. Thyroid Neoplasms / complications
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Bone Marrow / pathology. Female. Histocytochemistry. Humans. Immunohistochemistry. Leukemia. Middle Aged. Neck / radiography. Thyroid Nodule. Tomography

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090241.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


5. Alexandrova K, Griesel C, Barthold M, Heuft HG, Ott M, Winkler M, Schrem H, Manns MP, Bredehornsp T, Net M, Vidal MMI, Kafert-Kasting S, Arseniev L: Large-Scale Isolation of Human Hepatocytes for Therapeutic Application. Cell Transplant; 2005 Nov;14(10):845-853

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the last decade, hepatocyte transplantation has been suggested as a safe and potentially effective clinical option for the treatment of acute or decompensating chronic liver failure as well as for hereditary liver disease.
  • Currently, one of the major limiting factors for clinical application is the insufficient access to suitable liver cell preparations.
  • In about 50% of the cases (n = 58) the three-step perfusion procedure has been completed with an average total cell yield of 5.9 × 109 cells per organ, the cell preparations displaying a mean viability of 64%.
  • Specific cell yields from three infantile donor livers were considerably higher.
  • No correlation between isolation efficiency and cold ischemia time or donor age was found within the adult organ donors.
  • In contrast, organs with a severe steatosis generally did not result in successful cell isolation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28849979.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cell transplantation / GMP / Hepatocyte isolation / Steatosis
  •  go-up   go-down


6. Higuchi M, Matsuda T, Mori N, Yamada Y, Horie R, Watanabe T, Takahashi M, Oie M, Fujii M: Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation. Retrovirology; 2005;2:29
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation.
  • BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1) is associated with the development of adult T-cell leukemia (ATL).
  • HTLV-1 encoded Tax1 oncoprotein activates the transcription of genes involved in cell growth and anti-apoptosis through the NF-kappaB pathway, and is thought to play a critical role in the pathogenesis of ATL.
  • RESULTS: Using enhanced green fluorescent protein (EGFP) expression and blasticidin-resistance as selection markers, several retroviral cDNA clones exhibiting constitutive NF-kappaB activity in Rat-1 cells, including full-length CD30, were obtained from an ATL cell line.
  • [MeSH-major] Antigens, CD30 / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. NF-kappa B / metabolism. Up-Regulation
  • [MeSH-minor] Animals. Cell Line. Fibroblasts. Human T-lymphotropic virus 1 / pathogenicity. Humans. Jurkat Cells. Rats. T-Lymphocytes. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1986 Nov;5(11):2883-8 [3024966.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2451-9 [12193714.001]
  • [Cites] Cell. 1987 Apr 10;49(1):47-56 [3030566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] Leuk Lymphoma. 2002 Jul;43(7):1355-66 [12389614.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1019-27 [12689928.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1570-4 [14638696.001]
  • [Cites] Trends Immunol. 2004 Jun;25(6):280-8 [15145317.001]
  • [Cites] Neoplasia. 2004 May-Jun;6(3):266-78 [15153339.001]
  • [Cites] J Virol. 2004 Jun;78(12):6081-90 [15163701.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):355-9 [15251128.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):221-8 [6088403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [2787512.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):869-74 [2159438.001]
  • [Cites] Oncogene. 1991 Jun;6(6):1023-9 [1906155.001]
  • [Cites] Leuk Res. 1991;15(7):619-25 [1861543.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] J Virol. 1993 Mar;67(3):1211-7 [8437212.001]
  • [Cites] Oncogene. 1993 Dec;8(12):3189-97 [7504230.001]
  • [Cites] Leukemia. 1994 Dec;8(12):2083-94 [7528856.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):303-10 [7866279.001]
  • [Cites] Oncogene. 1995 Mar 16;10(6):1199-207 [7700645.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1865-70 [7703492.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9146-50 [7568090.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):873-87 [8631308.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1645-52 [8622884.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2422-32 [8839832.001]
  • [Cites] Leuk Lymphoma. 1996 May;21(5-6):443-7 [9172809.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2048-59 [9058727.001]
  • [Cites] Virology. 1997 Apr 28;231(1):135-40 [9143312.001]
  • [Cites] Oncogene. 1997 May 1;14(17):2071-8 [9160887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2452-7 [9482906.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):15891-4 [9632633.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16968-75 [9642260.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9319-24 [9689078.001]
  • [Cites] J Virol. 1998 Nov;72(11):8852-60 [9765430.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1063-71 [10190897.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):7981-7 [10482545.001]
  • [Cites] J Virol. 1999 Dec;73(12):9917-27 [10559304.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3847-54 [10572100.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1448-56 [10723136.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1063-6 [10871756.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21081-5 [10887201.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1591-6 [11080796.001]
  • [Cites] Blood. 2001 Feb 15;97(4):987-93 [11159527.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2602-9 [11160322.001]
  • [Cites] Mol Cell. 2001 Feb;7(2):401-9 [11239468.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2055-67 [11360190.001]
  • [Cites] Virus Genes. 2001 Jun;22(3):279-87 [11450946.001]
  • [Cites] Virus Genes. 2001;23(2):123-35 [11724264.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6805-15 [11726516.001]
  • [Cites] Nature. 2002 Mar 14;416(6877):190-4 [11894097.001]
  • [Cites] Nature. 2002 Mar 14;416(6877):194-9 [11894098.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2493-503 [11971184.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1647-54 [12000717.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):378-85 [11992406.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] Cell. 1987 Jan 30;48(2):343-50 [3026643.001]
  • (PMID = 15876358.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / NF-kappa B
  • [Other-IDs] NLM/ PMC1274245
  •  go-up   go-down


7. Taylor G: Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma. J Clin Pathol; 2007 Dec;60(12):1392-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma.
  • Human T-cell lymphotropic virus-I (HTLV-I) is the cause of adult T-cell leukaemia/lymphoma.
  • [MeSH-major] HTLV-I Infections / complications. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adult. Apoptosis. Cell Cycle / genetics. Cell Transformation, Neoplastic. Cell Transformation, Viral. Gene Products, tax / physiology. Genomic Instability. Humans. Transcription Factors / physiology. Viral Regulatory and Accessory Proteins / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1757-64 [11080823.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35926-31 [10931836.001]
  • [Cites] Virology. 2001 Jan 5;279(1):38-46 [11145887.001]
  • [Cites] J Immunol. 2001 Feb 1;166(3):1723-9 [11160217.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2602-9 [11160322.001]
  • [Cites] J Virol. 1992 Mar;66(3):1294-302 [1738191.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] J Biol Chem. 1992 Aug 15;267(23):16288-91 [1644814.001]
  • [Cites] J Virol. 1992 Oct;66(10):6191-3 [1527856.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Oncogene. 1993 Nov;8(11):3029-36 [8414503.001]
  • [Cites] J Virol. 1993 Dec;67(12):7001-7 [8230424.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Oncogene. 1993 Dec;8(12):3189-97 [7504230.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1013-23 [8137420.001]
  • [Cites] J Virol. 1994 May;68(5):3374-9 [8151796.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):14946-50 [8195127.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3120-30 [12218129.001]
  • [Cites] J Virol. 2002 Dec;76(24):12813-22 [12438606.001]
  • [Cites] Oncogene. 2003 Jun 12;22(24):3734-41 [12802280.001]
  • [Cites] J Virol. 2003 Oct;77(20):11027-39 [14512551.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43620-7 [12937177.001]
  • [Cites] J Gen Virol. 2003 Dec;84(Pt 12):3203-14 [14645902.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6629-34 [15100416.001]
  • [Cites] J Virol. 2004 Jun;78(12):6081-90 [15163701.001]
  • [Cites] J Virol. 2004 Oct;78(20):11077-83 [15452228.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2523-31 [15226182.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Princess Takamatsu Symp. 1982;12:285-94 [6984702.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Blood. 1988 Nov;72(5):1805-16 [2846094.001]
  • [Cites] J Virol. 1989 Aug;63(8):3220-6 [2501514.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1082-4 [2309119.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):121-9 [2358774.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] Gene. 2007 Jan 15;386(1-2):191-201 [17071021.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):4185-92 [17145747.001]
  • [Cites] Oncogene. 1995 Jan 19;10(2):269-77 [7838527.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68 [7531462.001]
  • [Cites] Virus Genes. 1995 Jan;9(2):161-70 [7732661.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3744-50 [8670878.001]
  • [Cites] Virology. 1997 Apr 28;231(1):135-40 [9143312.001]
  • [Cites] Oncogene. 1997 May 15;14(19):2265-72 [9178902.001]
  • [Cites] J Gen Virol. 1997 Dec;78 ( Pt 12):3277-85 [9400978.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] J Virol. 1998 May;72(5):4458-62 [9557741.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3620-32 [9584203.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14119-29 [9603911.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4701-7 [9616168.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22382-8 [9712859.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3993-4000 [9731513.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):525-40 [15580311.001]
  • [Cites] J Virol. 2005 Aug;79(15):9449-57 [16014908.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [16407133.001]
  • [Cites] J Biol Chem. 2006 Mar 31;281(13):8927-38 [16436385.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Virus Genes. 2001 Jun;22(3):279-87 [11450946.001]
  • [Cites] Blood. 2001 Aug 1;98(3):823-9 [11468184.001]
  • [Cites] J Virol. 2001 Oct;75(20):9885-95 [11559821.001]
  • [Cites] Virus Genes. 2001;23(2):123-35 [11724264.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5187-93 [11729202.001]
  • [Cites] J Virol. 2002 Apr;76(7):3493-501 [11884573.001]
  • [Cites] J Virol. 2002 Apr;76(8):4022-33 [11907241.001]
  • [Cites] J Biomed Sci. 2002 Jul-Aug;9(4):292-8 [12145525.001]
  • [Cites] Retrovirology. 2007;4:14 [17306025.001]
  • [Cites] J Virol. 2007 Jun;81(11):5714-23 [17344291.001]
  • [Cites] J Virol. 2007 Jun;81(11):6089-98 [17376895.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1752-62 [17554373.001]
  • [Cites] Retrovirology. 2007;4:49 [17634129.001]
  • [Cites] J Virol. 2007 Sep;81(17):9088-99 [17582004.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] J Virol. 1999 Dec;73(12):9917-27 [10559304.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5967-72 [10557085.001]
  • [Cites] J Gen Virol. 1999 Dec;80 ( Pt 12):3073-81 [10567637.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):319-24 [10652420.001]
  • [Cites] J Virol. 2000 May;74(9):3933-40 [10756004.001]
  • [Cites] Oncogene. 2000 Apr 27;19(18):2240-8 [10822374.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2849-55 [11023521.001]
  • [Cites] J Virol. 2000 Dec;74(23):11270-7 [11070026.001]
  • (PMID = 18042695.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Transcription Factors; 0 / Viral Regulatory and Accessory Proteins; 0 / tax protein, Human T-lymphotrophic virus 1
  • [Number-of-references] 91
  • [Other-IDs] NLM/ PMC2095577
  •  go-up   go-down


8. Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Takeshita M, Suzumiya J, Utsunomiya A, Kikuchi M, Ohshima K: The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol; 2008 May;21(5):617-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma is an aggressive malignant disease associated with regulatory T cells as discussed in some recent reports.
  • We analyzed the expression of FOXP3, a key molecule of regulatory T cells, in adult T-cell leukemia/lymphoma and its association with clinicopathological features.
  • Of 169 adult T-cell leukemia/lymphoma cases examined, 60 (36%) showed FOXP3 expression in lymphoma cells.
  • Morphologically, 22 cases were classified as anaplastic large cell variant and 147 as pleomorphic cell variant.
  • Only 1 (5%) of the anaplastic large cell variant cases and 59/147 (40%) of the pleomorphic cell variant cases expressed FOXP3.
  • FOXP3 expression in adult T-cell leukemia/lymphoma thus reflects morphological features and is clinically and pathologically associated with an immunosuppressive state.
  • [MeSH-major] Forkhead Transcription Factors / biosynthesis. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Southern. Epstein-Barr Virus Infections / metabolism. Female. Herpesvirus 4, Human. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246047.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


9. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW: FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res; 2008 Nov;32(11):1751-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
  • Engineered FBXW7 null cells display cell cycle and chromosome stability defects.
  • Mutations of FBXW7 have been found in human colorectal, ovarian, endometrial tumors and T-cell acute lymphocytic leukemias.
  • Prompted by these findings we have examined acute myeloid leukemia, non-Hodgkin's lymphoma, T-cell acute lymphocytic leukemia, B-cell acute lymphocytic leukemia and adult T-cell leukemia DNA for mutations of the FBXW7 gene.
  • As expected, mutations were found in T-cell acute lymphocytic leukemias.
  • However mutations of FBXW7 were also found in four of 118 B-cell acute lymphocytic leukemias and one of 24 adult T-cell leukemia samples.
  • These observations suggest that disruption of FBXW7 has a role in several forms of lymphocytic leukemias and not exclusively T-cell acute lymphocytic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Mutation / genetics. Ubiquitin-Protein Ligases / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485478.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


10. Perbellini O, Scupoli MT: Adult T-cell acute lymphoblastic leukemia: prognostic impact of myeloid-associated antigens. Expert Rev Hematol; 2009 Feb;2(1):27-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell acute lymphoblastic leukemia: prognostic impact of myeloid-associated antigens.
  • Despite the recent improvement in the treatment of the disease, the prognosis of adult T-cell acute lymphoblastic leukemia (T-ALL) remains poor.
  • The article under review analyzed the prognostic impact of myeloid-associated antigen expression in a monocentric cohort of adult T-ALL patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Acta Haematol. 2008;120(1):5-10 [18635939.001]
  • (PMID = 21082991.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Yamaguchi T, Maeda Y, Ueda S, Hijikata Y, Morita Y, Miyatake JI, Matsuda M, Kanamaru A: Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia. Leukemia; 2005 Jun;19(6):1010-7
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia.
  • We previously reported that all-trans retinoic acid (ATRA) inhibits growth in human T-cell leukemia virus type 1 (HTLV-1)-positive T-cell lines and fresh cells from patients with adult T-cell leukemia.
  • In the present study, we observed that NF-kappaB transcriptional activity as well as cell growth decreased significantly in HTLV-1-positive T-cell lines in the presence of ATRA.
  • SIL-2R was reduced by ATRA in both protein level (culture supernantant) and mRNA level in HTLV-1-positive T-cell lines.
  • Interestingly, ATRA significantly inhibited RT activity similar to azidothimidine (AZT) in HTLV-1-positive T-cell lines.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia, T-Cell / drug therapy. Leukemia, T-Cell / metabolism. Signal Transduction / drug effects. Tretinoin / pharmacology
  • [MeSH-minor] Adult. Cell Division / drug effects. Deltaretrovirus Infections / drug therapy. Deltaretrovirus Infections / metabolism. Deltaretrovirus Infections / physiopathology. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Viral / drug effects. Gene Products, gag / genetics. Gene Products, pol / genetics. Genes, pX / genetics. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / growth & development. Humans. In Vitro Techniques. Jurkat Cells. NF-kappa B / metabolism. Proviruses / genetics. Receptors, Interleukin-2 / metabolism. Solubility. Transcriptional Activation / drug effects. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843825.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gene Products, gag; 0 / Gene Products, pol; 0 / NF-kappa B; 0 / Receptors, Interleukin-2; 5688UTC01R / Tretinoin
  •  go-up   go-down


12. Shimizu D, Taki T, Utsunomiya A, Nakagawa H, Nomura K, Matsumoto Y, Nishida K, Horiike S, Taniwaki M: Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol; 2007 Apr;85(3):212-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma.
  • We analyzed NOTCH1 gene mutation in 53 adults with mature T-cell leukemia/lymphoma: 21 patients with adult T-cell leukemia (ATL), 25 with T-cell non-Hodgkin's lymphoma (T-NHL), and 7 with T-cell prolymphocytic leukemia.
  • We detected a nonsense mutation, C7249T (resulting in Q2417X, where X is a termination codon) in the PEST domain of NOTCH1 in an ATL patient and detected a 3-bp deletion (positions 7234-7236) that resulted in deletion of a proline codon at codon 2412 in the PEST domain of NOTCH1 in a patient with a T-NHL, peripheral T-cell lymphoma-unspecified (PTCL-u).
  • These findings suggest that nonsense mutation in the PEST domain in the ATL case was associated with NOTCH1 signaling through a pathway different from that for T-cell acute lymphoblastic leukemia (T-ALL).
  • Although NOTCH1 mutation occurs infrequently in mature T-cell leukemia/lymphoma, NOTCH1 may be involved in leukemogenesis associated with various forms of T-cell leukemia/lymphoma rather than only with T-ALL.
  • [MeSH-major] Codon, Nonsense. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Adult. DNA Mutational Analysis. Humans

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483057.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


13. Giam CZ, Jeang KT: HTLV-1 Tax and adult T-cell leukemia. Front Biosci; 2007;12:1496-507
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 Tax and adult T-cell leukemia.
  • Human T-lymphotropic virus type I (HTLV-1) is the etiological agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).
  • HTLV-1 viral transactivator/oncoprotein, Tax, activates viral transcription and usurps regulatory mechanisms that are critical for cell growth and division to facilitate viral replication.
  • The effects that Tax exerts on cells include potent NF-k B activation, cell cycle perturbation and cell transformation.
  • This review attempts to integrate recent literature on the biological activities of Tax and the properties of HTLV-1 transformed T-cells and ATL cells, and speculate on what cellular changes may collaborate with Tax to effect cell transformation and ATL development.
  • [MeSH-major] Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adult. Cell Transformation, Viral. HTLV-I Infections / metabolism. HTLV-I Infections / virology. Humans. NF-kappa B / metabolism. T-Lymphocytes / virology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127397.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA115884; United States / NCI NIH HHS / CA / R01CA75688; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / NF-kappa B
  • [Number-of-references] 129
  •  go-up   go-down


14. Zámecníkova A, Al Bahar S, Elshinnawy SE: Genomic instability and rapid clinical course in adult T-cell lymphoma/leukemia patient. Leuk Res; 2010 Dec;34(12):1617-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic instability and rapid clinical course in adult T-cell lymphoma/leukemia patient.
  • Adult T-cell leukemia/lymphoma is a distinct clinical entity characterized by a clonal proliferation of malignant T-lymphocytes.
  • The etiologic agent of the disease is a Human T-cell lymphotropic virus type I.
  • Karyotyping findings and their correlation with clinical features are still limited in T-cell malignancies, complicated by clinical heterogeneity and a plethora of secondary abnormalities.
  • This study describes detailed chromosomal and fluorescence in situ hybridization results observed in a patient with adult T-cell leukemia/lymphoma and correlates them with clinical characteristics.
  • [MeSH-major] Genomic Instability. HTLV-I Infections / genetics. Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / genetics. T-Lymphocytes
  • [MeSH-minor] Adult. Female. Humans. Karyotyping

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20211490.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Dungerwalla M, Osuji N, Waldman AD, Al Jehani F, Mehta A, Tailor R, Wotherspoon A, Cogill G, Matutes E: Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia. Br J Haematol; 2005 Aug;130(4):511-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia.
  • Central nervous system (CNS) presentation of adult T-cell lymphoma/leukaemia is rare, and almost invariably associated with systemic disease.
  • We report an unusual manifestation of adult T-cell lymphoma/leukaemia, with isolated CNS involvement and unusual imaging findings.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Disease Progression. Frontal Lobe / surgery. Humans. Interferons / therapeutic use. Magnetic Resonance Imaging. Male. Palliative Care. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2005 Nov;131(4):557. Taylor, R [corrected to Tailor, R]
  • (PMID = 16098064.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 9008-11-1 / Interferons
  • [Number-of-references] 22
  •  go-up   go-down


16. Beltran BE, Morales D, Quiñones P, Salas R, Castillo J: Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma.
  • : 8575 Background: Adult T-cell leukemia/lymphoma (ATLL) is associated with human T-cell lymphotropic virus type-I (HTLV-1) described in Southern Japan, Europe, Caribbean and South America.
  • Clinical types were acute (n=45), lymphomatous (n=43), cutaneous (n=10), smoldering (n=3) and chronic (n=1).
  • Median OS for acute, lymphomatous, smoldering and cutaneous subtype were 2, 11, 17 and 39 months, respectively (log-rank 28.5, p<0.00001).
  • The prognostic index for T-cell lymphoma (PIT) score was determined in 80 patients; 20 (25%), 17 (21%), 33 (41%) and 10 (13%) patients had scores of 0-1, 2, 3 and 4, respectively.
  • The IPI ant PIT scores, used for risk-stratification of aggressive B-cell and peripheral T-cell lymphomas, respectively, appear as good prognostic indicators for ATLL as well.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962272.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Vry J, Martínez-Martínez P, Losen M, Bode GH, Temel Y, Steckler T, Steinbusch HW, Baets M, Prickaerts J: Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain. Mol Ther; 2010 Jun;18(6):1183-1191

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain.
  • : Viral gene transfer or transgenic animals are commonly used technologies to alter gene expression in the adult brain, although these approaches lack spatial specificity and are time consuming.
  • We delivered plasmid DNA locally into the brain of adult C57BL/6 mice in vivo by voltage- and current-controlled electroporation.
  • In conclusion, low current-controlled electroporation is an excellent approach for electroporation in the adult brain, i.e., gene function can be influenced locally at a high level with no mortality and minimal tissue damage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178496.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Necchi A, Colecchia M, Nicolai N, Mego M, De Giorgi U, Mikuz G, Sava T, Di Nicola M, Pastorino U, Salvioni R: Somatic malignant differentiation in adult male germ-cell tumors (GCTs): Preliminary evidences from the INTera database (International Project for Teratoma with Malignant Transformation). J Clin Oncol; 2009 May 20;27(15_suppl):e16013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic malignant differentiation in adult male germ-cell tumors (GCTs): Preliminary evidences from the INTera database (International Project for Teratoma with Malignant Transformation).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962924.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kesserwan C, Sokolic R, Cowen E, Garabedian E, Pittaluga S, Baird K, López-Terrada D, Issekutz A, Bridge J, Wayne A, Candotti F: Dermatofibrosarcoma protuberans (DFSP) in six patients with ADA-SCID. J Clin Oncol; 2009 May 20;27(15_suppl):10570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All lesions showed a spindle cell proliferation of the dermis, extending into the subcutaneous fat.
  • A storiform pattern was only noticed in one adult patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963775.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Dodiya HB, Bjorklund T, Stansell Iii J, Mandel RJ, Kirik D, Kordower JH: Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates. Mol Ther; 2010 Mar;18(3):579-587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six intact young adult cynomolgus monkeys received a single 10 µl injection of AAV2/1-GFP, AAV2/5-GFP, or AAV2/8-GFP pseudotyped vectors into the caudate nucleus and putamen bilaterally in a pattern that resulted in each capsid serotype being injected into at least four striatal sites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182881.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Yasunami T, Wang YH, Tsuji K, Takanashi M, Yamada Y, Motoji T: Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leuk Res; 2007 Apr;31(4):465-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance protein expression of adult T-cell leukemia/lymphoma.
  • In adult T-cell leukemia/lymphoma (ATL), it is difficult to achieve remission and the reason for the resistance to chemotherapeutic agents may be linked to the presence of multidrug resistance (MDR) proteins.
  • [MeSH-major] Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Leukemia-Lymphoma, Adult T-Cell / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134750.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1; 80168379AG / Doxorubicin
  •  go-up   go-down


22. Sugita K, Shimauchi T, Tokura Y: Chronic actinic dermatitis associated with adult T-cell leukemia. J Am Acad Dermatol; 2005 Feb;52(2 Suppl 1):38-40
Genetic Alliance. consumer health - Leukemia, T-cell, chronic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic actinic dermatitis associated with adult T-cell leukemia.
  • We describe a patient with chronic actinic dermatitis that occurred with the progress of adult T-cell leukemia.
  • Immunohistochemically, CD8 + T cells, but not CD4 + cells, predominantly infiltrated the lichenoid lesional skin, indicating that the eruption was induced by reactive, normal CD8 + T cells but not adult T-cell leukemia cells.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Photosensitivity Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692511.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR4 protein, human; 0 / Cytokines; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


23. Yamada Y, Kamihira S: Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1553-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma.
  • Almost three decades have passed since adult T-cell leukemia-lymphoma (ATLL) was proposed as a new disease entity.
  • During this period, its causative agent, human T-cell leukemia virus type-1 (HTLV-1), was found and a crucial role of the viral product Tax in the development of ATLL was disclosed.
  • Recent progress in cell-cycle research has revealed that the uncontrolled and superior proliferative activity of malignant cells is mainly caused by the breakdown of cell-cycle regulation and that most malignancies carry aberrations in p16-pRB and/or p53 pathways.
  • ATLL is not an exception, despite the consistent association of HTLV-1 in primary leukemia cells, and accumulating evidence indicates that the breakdown of these pathways is indeed involved in the leukemogenesis of ATLL, especially in its later steps, which serve as the key events for promotion of indolent ATLL to aggressive ATLL.
  • [MeSH-major] Gene Silencing. Genes, Tumor Suppressor. Leukemia-Lymphoma, Adult T-Cell / etiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236609.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


24. Merle H, Donnio A, Gonin C, Jean-Charles A, Panelatti G, Plumelle Y: Retinal vasculitis caused by adult T-cell leukemia/lymphoma. Jpn J Ophthalmol; 2005 Jan-Feb;49(1):41-5
Genetic Alliance. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal vasculitis caused by adult T-cell leukemia/lymphoma.
  • BACKGROUND: To report a case of lymphomatous infiltration and bilateral retinal vasculitis observed among 83 cases of adult T-cell leukemia (ATL) treated in the University Hospital Center in Fort-de-France (Martinique, French West Indies) between 1984 and 2003.
  • CONCLUSION: Among the more than 300 seropositive for human T-cell lymphotropic virus type 1 (HTLV-1) or patients with HTLV-1-associated myelopathy/tropical spastic paraparesis treated at our hospital in the last 20 years, and among the 83 cases of ATL, only this single case of retinal vasculitis associated with HTLV-1 was observed (1/83, 1.2%) in Martinique, confirming the geographic variability of the clinical phenotype of HTLV-1 infection.
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / complications. Retinal Vasculitis / etiology
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Blotting, Western. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Fatal Outcome. Female. Fluorescein Angiography. HTLV-I Antibodies / blood. Humans. Leukemic Infiltration. Retina / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692773.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / HTLV-I Antibodies
  •  go-up   go-down


25. Ueda S, Maeda Y, Yamaguchi T, Hanamoto H, Hijikata Y, Tanaka M, Takai S, Hirase C, Morita Y, Kanamaru A: Influence of Epstein-Barr virus infection in adult T-cell leukemia. Hematology; 2008 Jun;13(3):154-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of Epstein-Barr virus infection in adult T-cell leukemia.
  • The involvement of adult T-cell leukemia (ATL) cells in organs such as the skin and lymph nodes is observed in about 50% of cases of ATL.
  • In this study, we established two B-cell lines from peripheral blood of patients with ATL.
  • To investigate the role of the interaction of these viruses, we transfected EBV and/or HTLV-1 into a healthy donor's lymphocytes, an EBV-infected B cell line, Raji, and a HTLV-1 negative T-cell line, Jurkat.
  • Furthermore, high levels of interleukin-4 (IL-4) were detected in these cell lines and transfectants.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Leukemia-Lymphoma, Adult T-Cell / complications
  • [MeSH-minor] Adult. Antigens, CD / genetics. B-Lymphocytes / pathology. B-Lymphocytes / virology. Cell Adhesion Molecules / genetics. Cell Line. Cell Line, Tumor. Gene Products, tax / genetics. Herpesvirus 4, Human / genetics. Human T-lymphotropic virus 1 / genetics. Humans. Intercellular Adhesion Molecule-1 / genetics. Macrophage-1 Antigen / genetics. Proviruses / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18702873.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cell Adhesion Molecules; 0 / Gene Products, tax; 0 / ICAM3 protein, human; 0 / Macrophage-1 Antigen; 0 / tax protein, Human T-lymphotrophic virus 1; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


26. Tawara M, Hogerzeil SJ, Yamada Y, Takasaki Y, Soda H, Hasegawa H, Murata K, Ikeda S, Imaizumi Y, Sugahara K, Tsuruda K, Tsukasaki K, Tomonaga M, Hirakata Y, Kamihira S: Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett; 2006 Mar 28;234(2):249-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma.
  • Based on statistical analysis of its age-dependent occurrence, a multi-step carcinogenesis model has been proposed for Adult T-cell Leukemia/Lymphoma (ATLL).
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosome Aberrations. Genes, p16. Genes, p53. Leukemia, T-Cell / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Polymorphism, Single-Stranded Conformational. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896902.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Barbeau B, Mesnard JM: Does the HBZ gene represent a new potential target for the treatment of adult T-cell leukemia? Int Rev Immunol; 2007 Sep-Dec;26(5-6):283-304

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the HBZ gene represent a new potential target for the treatment of adult T-cell leukemia?
  • Links between human T-cell leukemia virus type 1 and adult T-cell leukemia (ATL) were first suspected in 1980.
  • [MeSH-major] Basic-Leucine Zipper Transcription Factors / genetics. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / metabolism. Leukemia-Lymphoma, Adult T-Cell / virology. Viral Proteins / genetics
  • [MeSH-minor] Cell Proliferation. Gene Expression Regulation, Viral. Gene Products, tax / genetics. Gene Products, tax / metabolism. Genes, pX. Genome, Viral. Humans. T-Lymphocytes / cytology. T-Lymphocytes / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027202.001).
  • [ISSN] 0883-0185
  • [Journal-full-title] International reviews of immunology
  • [ISO-abbreviation] Int. Rev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Viral Proteins
  • [Number-of-references] 106
  •  go-up   go-down


28. Koga Y, Iwanaga M, Soda M, Inokuchi N, Sasaki D, Hasegawa H, Yanagihara K, Yamaguchi K, Kamihira S, Yamada Y: Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan. J Med Virol; 2010 Apr;82(4):668-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan.
  • Most previous studies aimed at estimating the number of human T-cell leukemia virus type-1 (HTLV-1) carriers in endemic areas have been based on seroprevalence rates in blood donors; however, this may result in underestimation because of the healthy donor effect.
  • The incidence of adult T-cell leukemia/lymphoma (ATLL) among HTLV-1 carriers was estimated using data from the Nagasaki Prefectural Cancer Registry.
  • [MeSH-major] HTLV-I Infections / complications. HTLV-I Infections / epidemiology. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / epidemiology. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carrier State / epidemiology. Child. Child, Preschool. Female. Hospitals. Humans. Incidence. Infant. Infant, Newborn. Japan. Male. Middle Aged. Seroepidemiologic Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20166187.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Okada J, Imafuku S, Tsujita J, Moroi Y, Urabe K, Furue M: Case of adult T-cell leukemia/lymphoma manifesting marked purpura. J Dermatol; 2007 Nov;34(11):782-5
MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of adult T-cell leukemia/lymphoma manifesting marked purpura.
  • Antibody to human T-lymphotropic virus type 1 (HTLV-1) was present in the serum and samples from skin lesions revealed HTLV-1 proviral DNA integration, as well as a clonal T-cell receptor Cbeta1 gene rearrangement.
  • We therefore diagnosed this case as adult T-cell leukemia/lymphoma (ATL), and the purpuric lesions as ATL-specific.
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Pigmentation Disorders / etiology. Purpura / etiology
  • [MeSH-minor] Blotting, Southern. Female. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Humans. Lymphocytes / immunology. Middle Aged. Skin / pathology. Skin / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17973821.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Chiaretti S, Messina M, Tavolaro S, Zardo G, Elia L, Vitale A, Fatica A, Gorello P, Piciocchi A, Scappucci G, Bozzoni I, Fozza C, Candoni A, Guarini A, Foà R: Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. Haematologica; 2010 Jul;95(7):1114-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223.
  • BACKGROUND: Until recently, few molecular aberrations were recognized in acute lymphoblastic leukemia of T-cell origin; novel lesions have recently been identified and a certain degree of overlap between acute myeloid leukemia and T-cell acute lymphoblastic leukemia has been suggested.
  • To identify novel T-cell acute lymphoblastic leukemia entities, gene expression profiling was performed and clinico-biological features were studied.
  • DESIGN AND METHODS: Sixty-nine untreated adults with T-cell acute lymphoblastic leukemia were evaluated by oligonucleotide arrays: unsupervised and supervised analyses were performed.
  • Of these, one branch included seven patients whose gene expression profile resembled that of acute myeloid leukemia.
  • We, therefore, evaluated the expression levels of miR-223, involved in myeloid differentiation: these cases had significantly higher levels of miR-223 than had the other cases of T-cell acute lymphoblastic leukemia, with values comparable to those observed in acute myeloid leukemia.
  • CONCLUSIONS: Using gene profiling we identified a subset of adult T-cell acute lymphoblastic leukemia, accounting for 10% of the cases analyzed, which displays myeloid features.
  • These cases were not recognized by standard approaches, underlining the importance of gene profiling in identifying novel acute leukemia subsets.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Leukemia, Myeloid, Acute / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adult. Humans


31. Kubuki Y, Suzuki M, Sasaki H, Toyama T, Yamashita K, Maeda K, Ido A, Matsuoka H, Okayama A, Nakanishi T, Tsubouchi H: Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma; 2005 Mar;46(3):393-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia.
  • The study was carried out in 22 patients with adult T-cell leukemia (ATL) (7 chronic and 15 acute types) and in 13 asymptomatic human T-lymphotropic virus type 1 (HTLV-1) carriers.
  • The mean values of TA in acute and chronic type patients were 13.8 and 1.6 total product generated (TPG) units, respectively, as determined by telomeric repeat amplification assays.
  • The mean TA value in acute type patients was significantly higher than in the three other subject groups.
  • The mean TL values in patients with acute and chronic types were 5.39 and 4.38 Kb, respectively, while the mean TL values in HTLV-1 carriers and healthy volunteers were 7.69 and 7.06 Kb, respectively.
  • Neither TA nor TL of ATL cells showed any significant association with the number of ATL cells, serum soluble interleukin-2 receptor, or serum lactate dehydrogenase in the peripheral blood of acute type patients.
  • The median survival period of acute ATL patients with high TA and shortened TL was 0.47 years, however, which was significantly shorter than that of acute ATL patients with low TA and normal TL (4.21 years) (p < 0.002).
  • [MeSH-major] HTLV-I Infections / enzymology. Leukemia-Lymphoma, Adult T-Cell / enzymology. Telomerase / metabolism. Telomere / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukocytes, Mononuclear / chemistry. Leukocytes, Mononuclear / enzymology. Male. Middle Aged. Prognosis. Prospective Studies. Restriction Mapping. Serologic Tests. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621829.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


32. Shimakage M, Inoue N, Ohshima K, Kawahara K, Yamamoto N, Oka T, Tambe Y, Yasui K, Matsumoto K, Yutsudo M, Inoue H: Downregulation of drs mRNA expression is associated with the progression of adult T-cell leukemia/lymphoma. Int J Oncol; 2007 Jun;30(6):1343-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of drs mRNA expression is associated with the progression of adult T-cell leukemia/lymphoma.
  • Although adult T-cell leukemia/lymphoma (ATLL) is initiated by infection with human T-cell leukemia virus (HTLV-1), many other factors are thought to be required for the progression from indolent ATL to aggressive ATLL.
  • In aggressive ATLL cell lines, expression of drs mRNA was not detected, although expression of drs mRNA was detected in T-cell lines infected with HTLV-1.
  • A correlation between drs downregulation and expression of the Tax gene was not observed in these T-cell lines.
  • Furthermore, introduction of drs into an ATL cell line, HUT102, by retrovirus vector suppressed the colony formation of the cells in soft agar and enhanced apoptotic cell death of the cells under low serum culture conditions.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, T-Cell / metabolism. Leukemia, T-Cell / pathology. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / pathology. Membrane Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Down-Regulation. Female. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487354.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / SRPX protein, human
  •  go-up   go-down


33. Haider S, Hayakawa K, Itoyama T, Sadamori N, Kurosawa N, Isobe M: TCR variable gene involvement in chromosome inversion between 14q11 and 14q24 in adult T-cell leukemia. J Hum Genet; 2006;51(4):326-34
Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TCR variable gene involvement in chromosome inversion between 14q11 and 14q24 in adult T-cell leukemia.
  • Chromosomal translocations in T-cell malignancies frequently involve the T-cell receptor (TCR)alpha/delta locus at chromosome 14q11.
  • Although 14q11 abnormalities are found in about 10% of adult T-cell leukemia (ATL) cases, until now there has been no direct evidence showing involvement of the TCR locus in ATL-a malignancy closely associated with HTLV-1 infection.
  • The breakpoints of T-cell malignancies most commonly occur within the Jalpha or Jdelta region of the TCR locus.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 14. Gene Expression Regulation, Leukemic. Genes, T-Cell Receptor. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] ADAM Proteins / metabolism. Adult. Animals. Base Sequence. Blotting, Southern. COS Cells. Cells, Cultured. Cercopithecus aethiops. DNA / genetics. Electrophoresis, Polyacrylamide Gel. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Leukocytes, Mononuclear / cytology. Membrane Proteins / metabolism. Models, Genetic. Molecular Sequence Data. Restriction Mapping. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520872.001).
  • [ISSN] 1434-5161
  • [Journal-full-title] Journal of human genetics
  • [ISO-abbreviation] J. Hum. Genet.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ202398/ DQ302756
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Membrane Proteins; 9007-49-2 / DNA; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins
  •  go-up   go-down


34. Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, Stetler-Stevenson M: Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am J Clin Pathol; 2010 Apr;133(4):592-601
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.
  • Little information exists regarding the detection of minimal residual disease (MRD) in adult T-cell leukemia/lymphoma (ATLL).
  • We evaluated 75 peripheral blood samples from 17 ATLL cases using flow cytometry (FC); 50 of the samples were concurrently evaluated by polymerase chain reaction (PCR) for clonal T-cell receptor gamma chain (TRG) gene rearrangement and the presence of human T-cell lymphotropic virus-1 proviral sequences.
  • Residual ATLL cells were identified using a multiparametric approach to identify aberrant T-cell immunophenotypes.
  • [MeSH-major] Flow Cytometry. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231613.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


35. Yang Y, Takeuchi S, Tsukasaki K, Yamada Y, Hata T, Mori N, Fukushima A, Seo H, Koeffler HP, Taguchi H: Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res; 2005 Jan;29(1):47-51
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma.
  • We investigated methylation status of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma (ATL).
  • APC methylation was found in 15 of 31 (48%) primary samples, and 2 of 4 (50%) ATL cell lines.
  • Methylation of the APC gene occurred more frequently in acute ATL (12/21) (57%) than chronic ATL (1/8) (13%) (P = 0.03).
  • APC was not expressed in the APC-methylated ATL cell line ST1.
  • Demethylation with 5-azacytidine treatment restored APC expression in the ST1 cell line.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / genetics. DNA Methylation. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Azacitidine / pharmacology. Cell Line, Tumor. CpG Islands / genetics. Disease Progression. Humans. Promoter Regions, Genetic. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2005 May;29(5):475-6 [15755498.001]
  • (PMID = 15541474.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; M801H13NRU / Azacitidine
  •  go-up   go-down


36. Komuro T, Okamoto S: Pure intracerebral mass lesion of adult T-cell leukemia/lymphoma--case report. Neurol Med Chir (Tokyo); 2010;50(6):492-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure intracerebral mass lesion of adult T-cell leukemia/lymphoma--case report.
  • A 48-year-old female presented with a rare case of adult T-cell leukemia/lymphoma (ATL) occurring as only intracerebral mass lesion manifesting as progressively worsening headaches, transient mild weakness of the left lower extremity, bilateral papilledema, and left homonymous hemianopsia.
  • Intracerebral ATL should be considered in the differential diagnosis of intracerebral mass without leukemia or systemic lymphoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Occipital Lobe / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20587977.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Roncador G, Garcia JF, Garcia JF, Maestre L, Lucas E, Menarguez J, Ohshima K, Nakamura S, Banham AH, Piris MA: FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia; 2005 Dec;19(12):2247-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma.
  • FOXP3 is a forkhead transcription factor family member, implicated in T-cell regulation, activation and differentiation.
  • FOXP3 expression in tumour cells was confined to adult T-cell leukaemia/lymphoma (ATLL) cases (17/25, 68%), with some variability in the intensity of the staining and the proportion of positive cells.
  • [MeSH-major] Forkhead Transcription Factors / analysis. Leukemia-Lymphoma, Adult T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193085.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


38. Horie R: NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma. Int Rev Immunol; 2007 Sep-Dec;26(5-6):269-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma.
  • Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) induces aberrant nuclear factor-kappaB (NF-kappaB) activation.
  • Blocking NF-kappaB not only induces apoptosis in adult T-cell leukemia/lymphoma (ATL) cells but also reduces the number of HTLV-1-infected cells in virus carriers.
  • [MeSH-major] Human T-lymphotropic virus 1 / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / therapy. NF-kappa B / metabolism
  • [MeSH-minor] Cell Proliferation. Gene Products, tax / metabolism. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027201.001).
  • [ISSN] 0883-0185
  • [Journal-full-title] International reviews of immunology
  • [ISO-abbreviation] Int. Rev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / NF-kappa B
  • [Number-of-references] 46
  •  go-up   go-down


39. Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, Takata K, Morito T, Huang X, Tamura M, Kitamura Y, Ohara N, Ouchida M, Ohshima K, Shimizu K, Tanimoto M, Takahashi K, Matsuoka M, Utsunomiya A, Yoshino T: Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol; 2010 Jan;176(1):402-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma.
  • However, little is known about the association of epigenetic abnormalities with multistep tumorigenic events in adult T cell leukemia/lymphoma (ATLL).
  • [MeSH-major] CpG Islands / genetics. DNA Methylation / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Base Sequence. Disease Progression. Gene Silencing. Genes, Neoplasm / genetics. Humans. Kaplan-Meier Estimate. Middle Aged. Models, Genetic. Molecular Sequence Data. Neoplasm Proteins / metabolism. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R28-49 [17613546.001]
  • [Cites] Int J Oncol. 2007 Jun;30(6):1343-8 [17487354.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1095-105 [18323801.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1523-7 [18754862.001]
  • [Cites] Nat Rev Genet. 2009 Jan;10(1):32-42 [19065135.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5965-75 [16155603.001]
  • [Cites] J Hum Genet. 1999;44(6):357-63 [10570904.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1043-8 [10706122.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1495-505 [11583976.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7241-6 [12370815.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6390-4 [12438221.001]
  • [Cites] J Virol. 2002 Dec;76(24):12813-22 [12438606.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:278-85 [12724232.001]
  • [Cites] Lancet Oncol. 2003 Jun;4(6):351-8 [12788407.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1551-6 [14507661.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1849-58 [14691303.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Apr;5(4):296-304 [15071554.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Jpn J Cancer Res. 1989 Mar;80(3):191-5 [2498254.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Virol. 1992 Nov;66(11):6686-94 [1404610.001]
  • [Cites] Jpn J Cancer Res. 1993 Jan;84(1):4-8 [8449826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] Blood. 1999 Jan 15;93(2):613-6 [9885223.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):1-13 [9973953.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] J Pathol. 2005 Jan;205(2):172-80 [15643671.001]
  • [Cites] J Infect Dis. 2005 Apr 1;191(7):1140-7 [15747250.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13928-35 [15691849.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):206-11 [15819717.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7043-9 [16192589.001]
  • [Cites] Retrovirology. 2006;3:5 [16409643.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Cancer Lett. 2006 Mar 28;234(2):249-55 [15896902.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4500-7 [16484591.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1058-64 [16861352.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1648-53 [16646068.001]
  • [Cites] Cell. 2007 Feb 23;128(4):735-45 [17320510.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2364-73 [18083845.001]
  • (PMID = 20019193.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2797900
  •  go-up   go-down


40. Kamihira S, Sugahara K, Tsuruda K, Minami S, Uemura A, Akamatsu N, Nagai H, Murata K, Hasegawa H, Hirakata Y, Takasaki Y, Tsukasaki K, Yamada Y: Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol; 2005 Aug;27(4):235-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells.
  • Human T-cell leukemia virus type-1 (HTLV-1) is the etiological agent of adult T-cell leukemia (ATL), and leukemic cells always carry the proviral genome monoclonally integrated into their host genomes at the same sequence site, designated as the monoclonal integration.
  • The incidence of the D- and M-types were in the order of smoldering, chronic, and acute subtypes of ATL, suggesting that such an aberrant proviral status is generated on the way to multistep carcinogenesis and is subsequently clinically important for the malignant behavior of the disease.
  • [MeSH-major] DNA, Viral / genetics. Genes, Viral. Human T-lymphotropic virus 1 / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. Proviruses / genetics
  • [MeSH-minor] Adult. Blotting, Southern. Cell Line, Tumor. Follow-Up Studies. Humans. In Situ Hybridization / methods. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048490.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


41. Kurihara K, Harashima N, Hanabuchi S, Masuda M, Utsunomiya A, Tanosaki R, Tomonaga M, Ohashi T, Hasegawa A, Masuda T, Okamura J, Tanaka Y, Kannagi M: Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer; 2005 Mar 20;114(2):257-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential immunogenicity of adult T cell leukemia cells in vivo.
  • Experimental vaccines targeting human T cell leukemia virus type-I (HTLV-I) Tax have been demonstrated in a rat model of HTLV-I-induced lymphomas.
  • However, the scarcity of HTLV-I-expression and the presence of defective HTLV-I-proviruses in adult T cell leukemia (ATL) cells have raised controversy about the therapeutic potential of HTLV-I-targeted immunotherapy in humans.
  • In flow cytometric analysis, we found that 3 of 5 acute-type and six of fifteen chronic-type ATL patients tested showed significant induction of HTLV-I Tax and Gag in their ATL cells in a 1-day culture.
  • Representative CTL epitopes restricted by HLA-A2 or A24 were conserved in 4 of 5 acute-type ATL patients tested.
  • Furthermore, spleen T cells from rats, which had been subcutaneously inoculated with formalin-fixed uncultured ATL cells, exhibited a strong interferon gamma-producing helper T cell responses specific for HTLV-I Tax-expressing cells.
  • Our study indicated that ATL cells from about half the patients tested readily express HTLV-I antigens including Tax in vitro, and that ATL cells express sufficient amounts of Tax or Tax-induced antigens to evoke specific T cell responses in vivo.
  • [MeSH-minor] Adult. Aged. Animals. Base Sequence. DNA Primers. Female. Humans. Japan. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia, Prolymphocytic, T-Cell / virology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / virology. Male. Middle Aged. Polymerase Chain Reaction. Rats. Rats, Inbred F344. Reference Values. Transplantation, Heterologous / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15551352.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


42. Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M, Tomonaga M, Harada M, Kimura N, Masuda M, Kawano F, Yufu Y, Hattori H, Kikuchi H, Saburi Y: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood; 2005 May 15;105(10):4143-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma.
  • Sixteen patients with adult T-cell leukemia/lymphoma (ATL) who were all over 50 years of age underwent allogeneic stem cell transplantation with reduced-conditioning intensity (RIST) from HLA-matched sibling donors after a conditioning regimen consisting of fludarabine (180 mg/m2), busulfan (8 mg/kg), and rabbit antithymocyte globulin (5 mg/kg).
  • After RIST, the human T-cell leukemia virus type 1 (HTLV-1) proviral load became undetectable in 8 patients.
  • [MeSH-major] Immunotherapy. Leukemia-Lymphoma, Adult T-Cell / therapy. Stem Cell Transplantation. Transplantation Conditioning

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665110.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Matsuo T, Kyoraku I, Shiomi K, Sugimoto S, Zheng HY, Nakazato M: [Detection of novel rearrangement of the JC virus gene in a case of progressive multifocal leukoencephalopathy with adult T-cell leukemia]. Rinsho Shinkeigaku; 2007 Jan;47(1):27-31
Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of novel rearrangement of the JC virus gene in a case of progressive multifocal leukoencephalopathy with adult T-cell leukemia].
  • A 53-year-old man with adult T-cell leukemia (ATL) developed progressive left hemiparesis and left homonymous hemianopsia.
  • [MeSH-major] Gene Rearrangement. JC Virus / genetics. Leukemia-Lymphoma, Adult T-Cell / complications. Leukoencephalopathy, Progressive Multifocal / genetics. Leukoencephalopathy, Progressive Multifocal / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491333.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron JM, Reman O, Cayuela JM, Lheritier V, Vernant JP, Fiere D, Macintyre E, Dombret H: Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood; 2005 Apr 15;105(8):3072-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.
  • Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leucemies Aigues Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course.
  • Representative patients with T-ALL (91 patients) were classified into surface T-cell receptor (TCR)-expressing T-ALL patients (TCRalphabeta+ or TCRgammadelta+), pre-alphabeta T-ALL patients (cTCRbeta+, TCR-), and immature (IM) cTCRbeta-, TCR- T-ALL patients; 81 patients underwent genotyping for SIL-TAL1, CALM-AF10, HOX11, and HOX11L2.
  • Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cytarabine / administration & dosage. Genotype. Humans. Immunophenotyping. Incidence. Middle Aged. Mitoxantrone / administration & dosage. Prospective Studies. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637138.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Receptors, Antigen, T-Cell; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


45. Chiaretti S, Tavolaro S, Ghia EM, Ariola C, Matteucci C, Elia L, Maggio R, Messina M, Ricciardi MR, Vitale A, Ritz J, Mecucci C, Guarini A, Foà R: Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. Haematologica; 2007 May;92(5):619-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.
  • BACKGROUND AND OBJECTIVES: Recent data have highlighted an involvement of ABL1 in T-cell acute lymphoblastic leukemia (T-ALL).
  • NUP214-ABL1, in adult T-ALL.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Leukemic. Genes, abl. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Proteins / biosynthesis. Oncogene Proteins, Fusion / biosynthesis. Proto-Oncogene Proteins c-abl / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Chromosomal Proteins, Non-Histone / biosynthesis. Chromosomal Proteins, Non-Histone / genetics. Clinical Trials as Topic / statistics & numerical data. Female. Fusion Proteins, bcr-abl / biosynthesis. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / biosynthesis. Homeodomain Proteins / genetics. Humans. In Situ Hybridization, Fluorescence. Intracellular Signaling Peptides and Proteins / genetics. Male. Multicenter Studies as Topic / statistics & numerical data. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Oncogene Proteins / biosynthesis. Oncogene Proteins / genetics. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488685.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Dek protein, human; 0 / EML1-ABL1 fusion protein, human; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / NUP214-ABL1 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / STIL protein, human; 0 / TLX3 protein, human; 143275-75-6 / TLX1 protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl
  •  go-up   go-down


46. Sakashita A, Ashizawa K, Minami K, Fukuda T, Fukuda M, Abe K, Hayashi T, Uetani M: Localized ground glass opacities with multiple pulmonary small cysts in adult T-cell leukemia or lymphoma: an "alloy wheel" appearance. J Thorac Imaging; 2009 Nov;24(4):321-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized ground glass opacities with multiple pulmonary small cysts in adult T-cell leukemia or lymphoma: an "alloy wheel" appearance.
  • We herein report a case of adult T-cell leukemia or lymphoma showing multiple lung cysts within a localized ground glass opacity (GGO) on computed tomography scan.
  • [MeSH-major] Cysts / radiography. Leukemia-Lymphoma, Adult T-Cell / radiography. Lung Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935228.001).
  • [ISSN] 1536-0237
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res; 2007 Jun;31(6):751-7
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL).
  • Multiple visceral involvements and various blood cell count abnormalities are frequently manifested in adult T-cell leukemia/lymphoma (ATLL) at diagnosis.
  • We evaluated the effects of four visceral involvement (bone marrow (BM), skin, liver, spleen) and six blood cell count abnormalities (anemia, neutrophilia, thrombocytopenia, monocytosis, eosinophilia, basophilia) on the overall survival of 168 ATLL patients.
  • [MeSH-major] Anemia / pathology. Bone Marrow / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukocyte Disorders / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. Skin / pathology. Spleen / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188352.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Adachi Y, Horio T: Chronic actinic dermatitis in a patient with adult T-cell leukemia. Photodermatol Photoimmunol Photomed; 2008 Jun;24(3):147-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic actinic dermatitis in a patient with adult T-cell leukemia.
  • However, clonal rearrangements of the T-cell receptors were not detected.
  • On the other hand, monoclonal integration of human T-cell lymphotrophic virus type I provirus was found in the peripheral lymphocytes.
  • In the present case, pseudolymphomatous changes occurred in association with adult T-cell leukemia.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Photosensitivity Disorders / complications. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Blotting, Southern. DNA, Viral / analysis. Human T-lymphotropic virus 1 / isolation & purification. Humans. Lymphocytes / pathology. Lymphocytes / virology. Male. Receptors, Antigen, T-Cell / genetics. Skin / pathology. Ultraviolet Rays

  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477134.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


49. Aljurf M, Zaidi SZ: Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. Biol Blood Marrow Transplant; 2005 Oct;11(10):739-54
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies.
  • Adult T-cell lymphoblastic lymphoma is a relatively rare aggressive type of non-Hodgkin lymphoma with frequent involvement of extranodal sites.
  • The collective experience in the management of adult T-cell lymphoblastic lymphoma suggests a good outcome for patients with no adverse prognostic factors who are treated with an acute lymphocytic leukemia-like treatment strategy.
  • Patients with adverse prognostic features should be considered for more aggressive therapy-specifically, high-dose chemotherapy and hematopoietic stem cell transplantation.
  • This article will attempt to review the current status of chemotherapy treatment programs and the relative merits of the different hematopoietic stem cell transplantation programs in this disease, particularly in relation to the pathologic and clinical features that correlate with disease prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Central Nervous System Neoplasms / therapy. Graft vs Tumor Effect. Humans. Mediastinal Neoplasms / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182175.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 114
  •  go-up   go-down


50. Morimoto H, Tsukada J, Kominato Y, Tanaka Y: Reduced expression of human mismatch repair genes in adult T-cell leukemia. Am J Hematol; 2005 Feb;78(2):100-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of human mismatch repair genes in adult T-cell leukemia.
  • In this study, we investigated the expression of six human DNA mismatch repair (MMR) genes, human MutS homologues 2 (hMSH2), 3 (hMSH3), and 6 (hMSH6), human MutL homologue 1 (hMLH1), human post-meiotic segregations 1 (hPMS1) and 2 (hPMS2), in primary leukemic cells obtained from 11 patients with acute-type adult T-cell leukemia (ATL) by using reverse transcription-polymerase chain reaction (RT-PCR).
  • [MeSH-major] Adenosine Triphosphatases / genetics. Base Pair Mismatch / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic. Leukemia-Lymphoma, Adult T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15682421.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / MSH3 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / PMS1 protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


51. Yonekura K, Kanekura T, Kanzaki T, Utsunomiya A: Crusted scabies in an adult T-cell leukemia/lymphoma patient successfully treated with oral ivermectin. J Dermatol; 2006 Feb;33(2):139-41
MedlinePlus Health Information. consumer health - Scabies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crusted scabies in an adult T-cell leukemia/lymphoma patient successfully treated with oral ivermectin.
  • We report an adult T-cell leukemia/lymphoma (ATL) patient whose crusted scabies was successfully treated with oral ivermectin.
  • [MeSH-major] Ivermectin / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Scabies / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556285.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 70288-86-7 / Ivermectin
  •  go-up   go-down


52. Yoshida M: Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia. Proc Jpn Acad Ser B Phys Biol Sci; 2010;86(2):117-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia.
  • A human retrovirus was established during 1980-1982 in linkage with a unique human leukemia, concurrently in Japan and USA.
  • This review covers our efforts on the discovery of new retrovirus, Human T-cell Leukemia Virus Type 1 (HTLV-1), first introducing to a new class of retroviruses with a unique regulatory factors, Tax and Rex.
  • Then it is followed by analyses of molecular interaction of the vial Tax with cellular machineries involved in the pathogenesis of Adult T-cell Leukemia (ATL).
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adult. Humans. Virus Replication

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1988 Jun 9;333(6173):504 [2836736.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3351-5 [2541443.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Cell. 1978 Feb;13(2):381-6 [203405.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Blood. 1981 Sep;58(3):645-7 [6455129.001]
  • [Cites] Cancer Genet Cytogenet. 1981 Apr;3(3):251-9 [6974589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Gan. 1981 Dec;72(6):978-81 [6281119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Int J Cancer. 1982 Jun 15;29(6):631-5 [6980846.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Nov;79(22):6899-902 [6294664.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Science. 1983 Dec 16;222(4629):1178 [6316504.001]
  • [Cites] Virology. 1984 Feb;133(1):238-41 [6322435.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [6326131.001]
  • [Cites] Nature. 1984 Jun 14-20;309(5969):640-2 [6328324.001]
  • [Cites] Hematol Oncol. 1983 Jul-Sep;1(3):193-204 [6329935.001]
  • [Cites] Science. 1984 Jul 27;225(4660):381-5 [6330891.001]
  • [Cites] Gan. 1984 Sep;75(9):747-51 [6094295.001]
  • [Cites] EMBO J. 1984 Dec 20;3(13):3231-7 [6098469.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Apr;82(8):2277-81 [2986109.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 May;82(10):3101-5 [2582407.001]
  • [Cites] Science. 1985 Jun 28;228(4707):1532-4 [2990031.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Virology. 1985 Jul 15;144(1):59-65 [2998047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(24):8359-63 [3001699.001]
  • [Cites] Jpn J Cancer Res. 1985 Dec;76(12):1127-31 [3005203.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4524-8 [3012571.001]
  • [Cites] EMBO J. 1986 Nov;5(11):2883-8 [3024966.001]
  • [Cites] FEBS Lett. 1986 Dec 15;209(2):187-90 [3025015.001]
  • [Cites] Cell. 1987 Jan 30;48(2):343-50 [3026643.001]
  • [Cites] J Virol. 1989 Aug;63(8):3234-9 [2545901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [2787512.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):413-7 [2403646.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(3):1071-5 [2300570.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1082-4 [2309119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5011-5 [1711215.001]
  • [Cites] Oncogene. 1992 Sep;7(9):1737-42 [1501885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3584-8 [8170951.001]
  • [Cites] Nature. 1994 Jul 21;370(6486):223-6 [7913207.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5967-72 [10557085.001]
  • [Cites] Virology. 2000 May 10;270(2):291-8 [10792988.001]
  • [Cites] J Virol. 2001 Jul;75(13):6086-94 [11390610.001]
  • [Cites] J Virol. 2002 Dec;76(24):12813-22 [12438606.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] J Mol Biol. 1976 Mar 5;101(3):349-65 [176368.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68 [7531462.001]
  • [Cites] Oncogene. 1995 Mar 16;10(6):1199-207 [7700645.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1607-14 [8612584.001]
  • [Cites] Virology. 1997 Apr 28;231(1):135-40 [9143312.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Virology. 1999 Jan 20;253(2):155-61 [9918874.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17402-5 [10364167.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4137-43 [10435595.001]
  • [Cites] J Virol. 1999 Oct;73(10):7981-7 [10482545.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5926-30 [16155599.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [16407133.001]
  • [Cites] Retrovirology. 2009;6:71 [19650892.001]
  • [Cites] AIDS Res. 1986 Dec;2 Suppl 1:S71-8 [3030350.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3653-7 [3035544.001]
  • [Cites] Annu Rev Immunol. 1987;5:541-59 [2885015.001]
  • [Cites] Biochim Biophys Acta. 1987 Jul 8;907(2):145-61 [2885029.001]
  • [Cites] Science. 1987 Sep 11;237(4820):1324-9 [2888190.001]
  • [Cites] EMBO J. 1988 Feb;7(2):519-23 [2835230.001]
  • (PMID = 20154469.001).
  • [ISSN] 1349-2896
  • [Journal-full-title] Proceedings of the Japan Academy. Series B, Physical and biological sciences
  • [ISO-abbreviation] Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 68
  • [Other-IDs] NLM/ PMC3417562
  •  go-up   go-down


53. Kawai K, Egawa N, Kiyono T, Kanekura T: Epidermodysplasia-verruciformis-like eruption associated with gamma-papillomavirus infection in a patient with adult T-cell leukemia. Dermatology; 2009;219(3):274-8
Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermodysplasia-verruciformis-like eruption associated with gamma-papillomavirus infection in a patient with adult T-cell leukemia.
  • We report a case of acquired EV-like eruption in an immunosuppressed patient with adult T-cell leukemia.
  • [MeSH-major] DNA, Viral / analysis. Epidermodysplasia Verruciformis / complications. Gammapapillomavirus / genetics. Leukemia-Lymphoma, Adult T-Cell / complications. Papillomavirus Infections / complications. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19696474.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


54. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, Lee J, Ambinder R, Campbell N, Lairmore M, AIDS Malignancy Consortium: Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One; 2009;4(2):e4420
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma.
  • BACKGROUND: Human T-cell leukemia virus-associated adult T-cell leukemia-lymphoma (ATLL) has a very poor prognosis, despite trials of a variety of different treatment regimens.
  • CONCLUSIONS: EPOCH chemotherapy followed by antiretroviral therapy is an active therapeutic regimen for adult T-cell leukemia-lymphoma, but viral reactivation during induction chemotherapy may contribute to treatment failure.
  • [MeSH-major] Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / virology. Virus Activation
  • [MeSH-minor] Adult. Antiviral Agents / pharmacology. Antiviral Agents / therapeutic use. DNA-Directed RNA Polymerases / metabolism. Disease Progression. Disease-Free Survival. Humans. Middle Aged. RNA, Viral / metabolism. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):209-17 [18510697.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2852-9 [15353320.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Leuk Res. 1992;16(5):435-41 [1625468.001]
  • [Cites] J Gen Virol. 1993 Nov;74 ( Pt 11):2531-7 [8245871.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1865-70 [7703492.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Virology. 2005 Aug 15;339(1):1-11 [15964046.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5952-64 [16155602.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1553-9 [16236609.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):381-7 [16052518.001]
  • [Cites] Adv Immunol. 2006;90:83-131 [16730262.001]
  • [Cites] Drug News Perspect. 2006 May;19(4):201-9 [16823495.001]
  • [Cites] Curr Drug Targets. 2006 Oct;7(10):1341-7 [17073596.001]
  • [Cites] Trends Mol Med. 2007 Jan;13(1):23-31 [17126603.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):90-9 [17222757.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):2052-7 [17278106.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] J Virol. 1999 Dec;73(12):10289-95 [10559346.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Infect Dis. 2001 Jan 15;183(2):197-205 [11120926.001]
  • [Cites] Blood. 2001 Feb 15;97(4):987-93 [11159527.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Antivir Ther. 2001;6 Suppl 3:25-44 [11678471.001]
  • [Cites] Blood. 2002 Jan 1;99(1):88-94 [11756157.001]
  • [Cites] J Infect Dis. 2002 Mar 1;185(5):691-5 [11865428.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2685-93 [11929754.001]
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):98-106 [17970785.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • (PMID = 19204798.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00041327
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083038; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / CA10521; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / P01 CA100730-07
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / RNA, Viral; EC 2.7.7.6 / DNA-Directed RNA Polymerases
  • [Other-IDs] NLM/ PMC2636875
  •  go-up   go-down


55. Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, Reman O, Witz F, Fagot T, Tavernier E, Turlure P, Leguay T, Huguet F, Vernant JP, Daniel F, Béné MC, Ifrah N, Thomas X, Dombret H, Macintyre E: NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood; 2009 Apr 23;113(17):3918-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
  • Many somatic genetic abnormalities have been identified in T-cell acute lymphoblastic leukemia (T-ALL) but each individual abnormality accounts for a small proportion of cases; therapeutic stratification consequently still relies on classical clinical markers.
  • We screened 141 adult diagnostic T-ALL samples from patients treated on either the Lymphoblastic Acute Leukemia in Adults (LALA)-94 (n = 87) or the GRAALL-2003 (n = 54) trials.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adult. Genotype. Humans. Mutation / genetics. Phenotype. Prognosis. Societies, Medical. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109228.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


56. Takatsuki K: Discovery of adult T-cell leukemia. Retrovirology; 2005;2:16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of adult T-cell leukemia.
  • Adult T-cell leukemia (ATL) was first reported as a distinct clinical entity in 1977 in Japan.
  • Central to the identification of the disease is a striking geographic clustering in southwestern Japan and the isolation of human T-cell lymphotropic virus type-1 (HTLV-1) from the cell lines of patients.
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / history
  • [MeSH-minor] Adult. History, 20th Century. Humans. Japan / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [CommentIn] Retrovirology. 2005;2:15 [15743525.001]
  • (PMID = 15743528.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC555581
  •  go-up   go-down


57. Arimura K, Arima N, Kukita T, Inoue H, Arai A, Matsushita K, Taguchi S, Yoshida H, Ozaki A, Kawada H, Akimoto M, Tei C: Fatal splenic rupture caused by infiltration of adult T cell leukemia cells. Acta Haematol; 2005;113(4):255-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal splenic rupture caused by infiltration of adult T cell leukemia cells.
  • The present report describes a fatal case of splenic rupture caused by infiltration of adult T cell leukemia cells and reports the mechanism of splenic rupture.
  • [MeSH-major] Leukemia, T-Cell / complications. Splenic Rupture / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel
  • (PMID = 15983432.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


58. Lin JH, Kim EJ, Bansal A, Seykora J, Richardson SK, Cha XY, Zafar S, Nasta S, Wysocka M, Benoit B, Rook AH, Fakharzadeh SS: Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor. Blood; 2008 Sep 15;112(6):2484-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor.
  • The oral rexinoid bexarotene (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL).
  • We recently reported the first case of adult T-cell leukemia/lymphoma (ATLL) that responded rapidly to combination therapy of bexarotene and interferon (IFN)-alpha2b with complete clinical response.
  • Our findings indicate that reduced expression of the RXR-alpha receptor subunit may represent a mechanism for resistance to bexarotene in T-cell malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6033-8 [11085524.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2456-71 [11331325.001]
  • [Cites] Arch Dermatol. 2001 May;137(5):581-93 [11346336.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1234-40 [12006543.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6376-80 [12438218.001]
  • [Cites] J Am Acad Dermatol. 2004 Mar;50(3):375-9 [14988678.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):380-4 [17038666.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4282-9 [9192750.001]
  • [Cites] Cell Death Differ. 2004 Dec;11 Suppl 2:S126-43 [15608692.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):301-4 [15781670.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):315-21 [15781672.001]
  • [Cites] Br J Dermatol. 2005 Jun;152(6):1199-205 [15948982.001]
  • [Cites] Curr Med Chem. 2006;13(21):2487-502 [17017906.001]
  • [Cites] Trends Genet. 1994 Feb;10(2):41-2 [8191583.001]
  • (PMID = 18559673.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100499; United States / NCI NIH HHS / CA / CA100499
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoid X Receptor alpha; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  • [Other-IDs] NLM/ PMC2532815
  •  go-up   go-down


59. Matsubar Y, Hori T, Morita R, Sakaguchi S, Uchiyama T: Delineation of immunoregulatory properties of adult T-cell leukemia cells. Int J Hematol; 2006 Jul;84(1):63-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delineation of immunoregulatory properties of adult T-cell leukemia cells.
  • We characterized leukemic cells from 20 adult T-cell leukemia (ATL) cases and 7 ATL-derived cell lines in terms of Foxp3 messenger RNA (mRNA) expression, cytokine production, cell surface markers associated with regulatory T-cells (Treg), and in vitro immunoregulatory activity and compared the results with those of cells from 3 T-cell-type chronic lymphocytic leukemia (T-CLL) patients and normal CD4+ T-cells.
  • Real-time polymerase chain reaction analysis showed that cells from 10 ATL cases, 1 T-CLL case, and 1 ATL cell line had higher Foxp3 mRNA levels than CD4+ T-cells.
  • [MeSH-major] Gene Expression Regulation, Leukemic / immunology. Immune Tolerance. Leukemia-Lymphoma, Adult T-Cell / immunology
  • [MeSH-minor] Aged. Cell Line, Tumor. Coculture Techniques. Female. Humans. Male. Middle Aged. T-Lymphocytes, Regulatory / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867905.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Miyahara H, Itou H, Sekine A, Taniyama D, Katsui T, Tanaka W, Satou R, Kurihara A, Satou Y, Sakamaki F: [A case of adult T-cell leukemia/lymphoma with primary lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):342-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult T-cell leukemia/lymphoma with primary lung cancer].
  • The mass was pathologically diagnosed as adult T-cell leukemia/lymphoma (ATLL) because of a high HTLV-1 antibody titer, and radiation therapy was started.
  • [MeSH-major] Adenocarcinoma / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455967.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Yamaguchi T, Ohshima K, Karube K, Tutiya T, Kawano R, Suefuji H, Shimizu A, Nakayama J, Suzumiya J, Moroi Y, Urabe K, Furue M, Koga T, Kikuchi M: Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/ lymphoma. Br J Dermatol; 2005 Jan;152(1):76-81
Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/ lymphoma.
  • BACKGROUND: Adult T-cell leukaemia/lymphoma (ATLL) is a human malignancy associated with human T-cell leukaemia virus type I (HTLV-I).
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Skin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Viral / analysis. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Male. Middle Aged. Prognosis. Proviruses / isolation & purification. Survival Analysis. Virus Integration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15656804.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


62. Ravandi F, Faderl S: Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res; 2006 Jan;30(1):103-5
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.
  • Treatment of adult T-cell leukemia (ATL) remains difficult.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979704.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab
  •  go-up   go-down


63. Kawahara M, Hori T, Matsubara Y, Okawa K, Uchiyama T: Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia. J Immunother; 2007 Jul-Aug;30(5):499-505
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
  • In the present study, we attempted a comprehensive analysis of human leukocyte antigen (HLA) class I-bound peptides presented on adult T-cell leukemia (ATL) cells by the latest technology of mass spectrometry combined with reversed phase liquid chromatography (LC/MS) to identify novel tumor-associated antigens.
  • Among these candidates, we focused on cyclin-dependent kinaselike 5 (CDKL5) because it was highly expressed in several ATL cell lines and some ATL clinical samples but not in normal CD4 T cells.
  • CDKL5-stimulated bulk CD8 T cells exerted higher cytotoxicity against CDKL5 peptide-loaded autologous Epstein Barr virus-transformed B cell line (LCL) than against unloaded LCL.
  • These results demonstrate that CDKL5 is a novel tumor (leukemia) antigen in ATL and that the HLA-B*62-restricted CDKL5 peptide can be used for cytotoxic T-lymphocyte-mediated immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / immunology. Histocompatibility Antigens Class I / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. Peptides / analysis. Protein-Serine-Threonine Kinases / immunology
  • [MeSH-minor] B-Lymphocytes. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / immunology. Cell Line. Cell Line, Transformed. Cell Line, Tumor. Chromatography, Liquid. Cytotoxicity, Immunologic. Dendritic Cells / immunology. HLA-B Antigens / immunology. Herpesvirus 4, Human. Humans. Immunotherapy. Mass Spectrometry. Oligopeptides / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17589290.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-B Antigens; 0 / Histocompatibility Antigens Class I; 0 / Oligopeptides; 0 / Peptides; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDKL5 protein, human
  •  go-up   go-down


64. Takizawa J, Aoki S, Kurasaki T, Higashimura M, Honma K, Kitajima T, Momoi A, Takahashi H, Nakamura N, Furukawa T, Aizawa Y: Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation. Am J Hematol; 2007 Dec;82(12):1113-5
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation.
  • This study reports the first well-documented case of adult T-cell leukemia (ATL) successfully treated with unrelated cord blood transplantation (UCBT).
  • A 49-year-old woman was diagnosed with acute-type of ATL.
  • Chemotherapy induced complete remission, but the human T-cell leukemia virus type 1 (HTLV-1) proviral load was detected in mononuclear cells of her peripheral blood.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696205.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


65. Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP, Taguchi H: Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res; 2007 May;31(5):673-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
  • This study found that phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling was activated in human T-cell lymphotropic virus type I (HTLV-1)-infected leukemia cells.
  • Rapamycin (1-100 nM, 48h), the inhibitor of mTOR and its analog RAD001 (1-100 nM, 48 h)-induced growth inhibition and G0/G1 cell cycle arrest of these cells in association with de-phosphorylation of p70S6K and 4E-BP-1, although IC50 was not achieved.
  • Blockade of Akt signaling by the PI3K inhibitor LY294002 (1-20 microM, 48 h) also resulted in the growth inhibition and G0/G1 cell cycle arrest of HTLV-1-infected cells, with IC50 ranging from 5 to 20muM, and it caused de-phosphorylation of p70S6K and 4E-BP-1.
  • Moreover, both LY294002 and rapamycin down-regulated the levels of c-Myc and cyclin D1 proteins in these cells, and their combination further decreased levels of these cell cycle-regulating proteins.
  • Taken together, longitudinal inhibition of PI3K/Akt/mTOR signaling represents a promising treatment strategy for individuals with adult T-cell leukemia.
  • [MeSH-major] Chromones / pharmacology. Leukemia-Lymphoma, Adult T-Cell / pathology. Morpholines / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein Kinases. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Sirolimus / pharmacology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Cell Cycle / drug effects. Cyclin D. Cyclins / metabolism. Enzyme Inhibitors / pharmacology. Human T-lymphotropic virus 1. Humans. Immunosuppressive Agents / pharmacology. Phosphoproteins / metabolism. Phosphorylation / drug effects. Proto-Oncogene Proteins c-myc / metabolism. Ribosomal Protein S6 Kinases, 70-kDa / antagonists & inhibitors. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Signal Transduction / drug effects. T-Lymphocytes / metabolism. T-Lymphocytes / virology. TOR Serine-Threonine Kinases. Tumor Cells, Cultured

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007924.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Chromones; 0 / Cyclin D; 0 / Cyclins; 0 / EIF4EBP1 protein, human; 0 / Enzyme Inhibitors; 0 / Immunosuppressive Agents; 0 / MYC protein, human; 0 / Morpholines; 0 / Phosphoproteins; 0 / Proto-Oncogene Proteins c-myc; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


66. Taniguchi A, Nemoto Y, Yokoyama A, Kotani N, Imai S, Shuin T, Daibata M: Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia. Int J Cancer; 2008 Oct 15;123(8):1824-31
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia.
  • Bone morphogenetic proteins (BMP), belonging to the transforming growth factor-beta superfamily, are multifunctional regulators of cell proliferation, differentiation and apoptosis in various types of malignant cells.
  • The BMP-6 methylation was found preferentially in adult T-cell leukemia (ATL) (49 of 60, 82%) compared with other types of leukemias studied including acute myeloid leukemia (3 of 67, 5%), acute lymphoblastic leukemia (6 of 38, 16%) and chronic lymphocytic leukemia (1 of 21, 5%).
  • Among subtypes of ATL, the BMP-6 gene was more frequently methylated in aggressive ATL forms of acute (96%) and lymphoma (94%) types than less malignant chronic ATL (44%) and smoldering ATL (20%).
  • [MeSH-major] Bone Morphogenetic Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Base Sequence. Bone Morphogenetic Protein 6. DNA Methylation. Female. Gene Expression Regulation, Leukemic / drug effects. Gene Silencing. Humans. Male. Middle Aged. Molecular Sequence Data. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Sequence Analysis, DNA / methods. Sulfites / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688853.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP6 protein, human; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Proteins; 0 / RNA, Messenger; 0 / Sulfites; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine; OJ9787WBLU / hydrogen sulfite
  •  go-up   go-down


67. Nakahata S, Yamazaki S, Nakauchi H, Morishita K: Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene; 2010 Jul 22;29(29):4157-69
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.
  • Zinc-finger E-box binding homeobox 1 (ZEB1) is a candidate tumor-suppressor gene in adult T-cell leukemia/lymphoma (ATLL).
  • Conversely, because ZEB1 mRNA was detected in the late stages of T-cell development, we used CTLL2 cells with ZEB1 expression, a murine peripheral T-cell lymphoma, and found that a complex of Smad3, Smad7 and ZEB1 was bound to the SRE of the p21(CDKN1A) promoter after the induction of Smad7 by TGF-beta1 treatment.
  • [MeSH-major] Homeodomain Proteins / physiology. Leukemia-Lymphoma, Adult T-Cell / pathology. Smad7 Protein / physiology. Transcription Factors / physiology. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Down-Regulation. Humans. Plasminogen Activator Inhibitor 1 / genetics. Promoter Regions, Genetic. RNA, Messenger / analysis. Signal Transduction. Smad3 Protein / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncogene. 2011 Jun 23;30(25):2900
  • (PMID = 20514018.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Homeodomain Proteins; 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Messenger; 0 / SMAD3 protein, human; 0 / SMAD7 protein, human; 0 / Smad3 Protein; 0 / Smad7 Protein; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / ZEB1 protein, human
  •  go-up   go-down


68. Richard V, Nadella MV, Green PL, Lairmore MD, Feuer G, Foley JG, Rosol TJ: Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia; 2005 Jul;19(7):1175-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma.
  • Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy seen in the majority of adult T-cell leukemia/lymphoma (ATLL) patients with human T-cell lymphotropic virus type-1 (HTLV-1) infection.
  • In this study, we report an inverse correlation of PTHrP with tax/rex mRNA in multiple HTLV-1-positive cell lines and RV-ATL cells.
  • Our data demonstrate that transcriptional regulation of PTHrP in ATLL cells can be controlled by T-cell receptor signaling and the ETS and MAPK ERK pathway in a Tax-independent manner.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Endocrinology. 2000 May;141(5):1882-92 [10803599.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1583-90 [11080795.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46661-70 [11590145.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):799-805 [12632071.001]
  • [Cites] Mol Cell Endocrinol. 2003 Jun 30;204(1-2):155-68 [12850290.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Oct;81(19):6207-11 [6091140.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):556-63 [3043221.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Gene. 1989 Apr 15;77(1):95-105 [2744490.001]
  • [Cites] J Immunol. 1989 Aug 15;143(4):1283-9 [2545785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [2787512.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):219-27 [2788697.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Mar 30;167(3):1134-8 [2322262.001]
  • [Cites] J Virol. 1990 Jun;64(6):2825-32 [2335818.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Mol Endocrinol. 1990 Jun;4(6):851-8 [2233743.001]
  • [Cites] J Biol Chem. 1992 Jul 5;267(19):13623-8 [1618864.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1642-52 [1280327.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;182:421-4 [1490380.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1017-24 [8427983.001]
  • [Cites] Cancer. 1993 May 1;71(9):2803-6 [8467460.001]
  • [Cites] Mol Endocrinol. 1993 Feb;7(2):273-82 [8469240.001]
  • [Cites] Endocrinology. 1993 Jun;132(6):2551-6 [8099324.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):2980-6 [8319205.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16730-6 [8393873.001]
  • [Cites] J Virol. 1993 Oct;67(10):6087-95 [8371355.001]
  • [Cites] Urology. 1994 May;43(5):675-9 [8165768.001]
  • [Cites] J Bone Miner Res. 1994 May;9(5):639-44 [8053392.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8960-3 [8090753.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1782-9 [7895691.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4064-75 [7623802.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2257-67 [7662973.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):702-7 [7669584.001]
  • [Cites] Mol Cell Endocrinol. 1995 Jun;111(2):225-32 [7556886.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] J Cell Physiol. 1996 Jan;166(1):1-11 [8557757.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1349-57 [8625910.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3744-50 [8670878.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11463-71 [9565558.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14119-29 [9603911.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):6015-22 [10606251.001]
  • [Cites] Mol Cell Endocrinol. 1999 Oct 25;156(1-2):13-23 [10612419.001]
  • (PMID = 15889157.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCI NIH HHS / CA / P01 CA100730-069003; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; United States / NCI NIH HHS / CA / P01 CA100730-03; None / None / / P01 CA100730-01; United States / NCI NIH HHS / CA / CA100730-03; United States / NCI NIH HHS / CA / P01 CA100730-01; United States / NCI NIH HHS / CA / CA100730-069003; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ETS1 protein, human; 0 / Ets1 protein, mouse; 0 / Gene Products, rex; 0 / Gene Products, tax; 0 / Parathyroid Hormone-Related Protein; 0 / Proto-Oncogene Protein c-ets-1; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RNA, Messenger; 0 / Receptors, Antigen, T-Cell; 0 / Transcription Factors; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS94146; NLM/ PMC2661941
  •  go-up   go-down


69. Utsunomiya A, Ishida T, Inagaki A, Ishii T, Yano H, Komatsu H, Iida S, Yonekura K, Takeuchi S, Takatsuka Y, Ueda R: Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res; 2007 Jul;31(7):915-20
MedlinePlus Health Information. consumer health - Eosinophilic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor.
  • We investigated the clinical significance of a blood eosinophilia in a cohort of 158 consecutive patients with adult T-cell leukemia/lymphoma (ATLL), and multivariate analysis revealed that a blood eosinophilia was an independent and a significant unfavorable prognostic factor.
  • [MeSH-major] Eosinophilia / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Cohort Studies. Eosinophils / pathology. Female. Humans. L-Lactate Dehydrogenase / blood. Leukocyte Count. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123603.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


70. Furukawa Y, Tara M, Izumo S, Arimura K, Osame M: HTLV-I viral escape and host genetic changes in the development of adult T cell leukemia. Int J Cancer; 2006 Jan 15;118(2):381-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-I viral escape and host genetic changes in the development of adult T cell leukemia.
  • In the pathogenesis of adult T cell leukemia (ATL), an oncogenetic role of the human T cell lymphotropic virus type I (HTLV-I) Tax protein, viral escape from the host immune system, and host genetic changes have been proposed as contributory factors.
  • We also examined deletion of cyclin-dependent kinase inhibitor 4 (INK4) genes and mutation of p53 gene in combination with changes in the HTLV-I genome in acute type ATL to test whether host genetic changes promoted the malignant transformation of ATL cells that carry putative CTL escape mutations.
  • [MeSH-major] Codon, Nonsense. Genes, pX / genetics. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Cell Proliferation. Cell Survival. Cyclin-Dependent Kinase Inhibitor Proteins / genetics. Cyclin-Dependent Kinase Inhibitor Proteins / physiology. Genes, p53. HTLV-I Infections / complications. Humans. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16052518.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / Cyclin-Dependent Kinase Inhibitor Proteins
  •  go-up   go-down


71. Matsuoka M: Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology; 2005;2:27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL).
  • The clinical entity of adult T-cell leukemia (ATL) was established around 1977, and human T-cell leukemia virus type 1 (HTLV-I) was subsequently identified in 1980.
  • [MeSH-major] Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell
  • [MeSH-minor] Adult. Female. Humans. Infant, Newborn. Virus Replication

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43998-4004 [15308664.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Oncogene. 1999 Jun 24;18(25):3766-72 [10391685.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4137-43 [10435595.001]
  • [Cites] J Virol. 1999 Oct;73(10):7981-7 [10482545.001]
  • [Cites] J Obstet Gynaecol Res. 2004 Dec;30(6):436-8 [15566458.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7529-39 [15569983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):63-8 [15623561.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):419-30 [15543232.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1001-10 [15592508.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):967-74 [15729715.001]
  • [Cites] J Virol. 2005 Jul;79(14):9346-50 [15994832.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1741-54 [10601350.001]
  • [Cites] Blood. 2000 Jan 1;95(1):30-8 [10607681.001]
  • [Cites] J Emerg Med. 2000 Jan;18(1):109-19 [10645850.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):319-24 [10652420.001]
  • [Cites] Annu Rev Genet. 1999;33:29-55 [10690403.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1043-8 [10706122.001]
  • [Cites] Oncogene. 2000 Mar 16;19(12):1491-9 [10734308.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3377-86 [10779327.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Immunity. 2000 Nov;13(5):657-64 [11114378.001]
  • [Cites] Blood. 2001 Feb 15;97(4):987-93 [11159527.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2137-44 [11264182.001]
  • [Cites] Mol Biol Evol. 2001 Apr;18(4):661-71 [11264418.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):869-75 [11275994.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3770-4 [11325850.001]
  • [Cites] Blood. 2001 May 15;97(10):3177-83 [11342446.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Proc Biol Sci. 2001 Jun 22;268(1473):1215-21 [11410146.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1200-8 [11493471.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4484-96 [11494144.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1775-83 [11734593.001]
  • [Cites] Blood. 2002 Jan 15;99(2):634-40 [11781248.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1505-11 [11861261.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1083-6 [11861386.001]
  • [Cites] J Virol. 2002 Mar;76(6):2648-53 [11861831.001]
  • [Cites] J Infect Dis. 2002 Mar 1;185(5):691-5 [11865428.001]
  • [Cites] Clin Infect Dis. 2002 Jun 15;34(12):1551-7 [12032888.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1481-93 [1540956.001]
  • [Cites] Blood. 1992 Dec 15;80(12):3205-16 [1361372.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):735-40 [8101469.001]
  • [Cites] Virology. 1993 Sep;196(1):25-33 [8356797.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):337-40 [8314320.001]
  • [Cites] Leukemia. 1995 Apr;9(4):598-604 [7723391.001]
  • [Cites] Blood. 1995 May 15;85(10):2699-704 [7742529.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1924-30 [7655021.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33766-75 [12097320.001]
  • [Cites] J Infect Dis. 2002 Oct 1;186(7):932-9 [12232833.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):657-63 [12296513.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1713-6 [12589003.001]
  • [Cites] Immunol Rev. 2003 Jun;193:58-69 [12752671.001]
  • [Cites] Blood. 2003 Jul 1;102(1):284-8 [12649132.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43620-7 [12937177.001]
  • [Cites] Transpl Int. 1992;5 Suppl 1:S450-3 [14621843.001]
  • [Cites] Cell. 2003 Nov 14;115(4):449-59 [14622599.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):280-96 [14686485.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):297-303 [14686486.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):495-508 [14530271.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):131-4 [6609759.001]
  • [Cites] Lancet. 1984 May 26;1(8387):1183-4 [6144909.001]
  • [Cites] Vox Sang. 1984;46(5):245-53 [6328765.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):181-5 [2981140.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1688-90 [2992744.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Cancer. 1987 Mar 15;59(6):1187-91 [2880656.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3653-7 [3035544.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3849-52 [2544261.001]
  • [Cites] Jpn J Ophthalmol. 1989;33(4):472-81 [2576286.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Lancet. 1990 Dec 1;336(8727):1345-7 [1978165.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] Leuk Res. 1991;15(9):837-46 [1656151.001]
  • [Cites] Blood. 1992 Jan 15;79(2):477-80 [1730092.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):873-87 [8631308.001]
  • [Cites] Jpn J Cancer Res. 1996 Mar;87(3):227-31 [8613423.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1607-14 [8612584.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2185-95 [8642328.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):713-5 [8826899.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3065-73 [8874205.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4862-7 [9354450.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):6698-703 [9506967.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Blood. 1998 May 15;91(10):3935-42 [9573032.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):3744-51 [9632757.001]
  • [Cites] Oncogene. 1998 Jul 9;17(1):77-82 [9671316.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3557-61 [9808547.001]
  • [Cites] Nat Med. 1999 Jan;5(1):11-2 [9883827.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):436-41 [9989410.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3848-53 [10097126.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1063-71 [10190897.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):859-64 [10362130.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):391-9 [14729650.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] Virology. 2004 Jan 5;318(1):327-36 [14972558.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] Mol Biol Evol. 2004 Mar;21(3):603-11 [14739252.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2753-60 [14656887.001]
  • [Cites] Int J Cancer. 2004 Jul 1;110(4):621-5 [15122598.001]
  • [Cites] Br J Haematol. 2004 Jul;126(1):81-4 [15198736.001]
  • [Cites] Trends Microbiol. 2004 Jul;12(7):346-52 [15223062.001]
  • [Cites] Blood. 2004 Aug 1;104(3):802-9 [15090453.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6002-9 [15342380.001]
  • [Cites] J Infect Dis. 2004 Oct 1;190(7):1275-8 [15346338.001]
  • [Cites] J Immunol. 2004 Oct 15;173(8):5121-9 [15470056.001]
  • (PMID = 15854229.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 129
  • [Other-IDs] NLM/ PMC1131926
  •  go-up   go-down


72. Kawakami T, Kawanabe T, Soma Y: Granuloma annulare-like skin lesions as an initial manifestation in a Japanese patient with adult T-cell leukemia/lymphoma. J Am Acad Dermatol; 2009 May;60(5):848-52
Genetic Alliance. consumer health - Granuloma Annulare.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granuloma annulare-like skin lesions as an initial manifestation in a Japanese patient with adult T-cell leukemia/lymphoma.
  • Histologic examination revealed epithelioid cell granulomas associated with dense atypical lymphocytes in the dermis.
  • Human T-cell leukemia virus type I proviral DNA was detected in the blood and cerebrospinal fluid by Southern blot analysis and polymerase chain reaction assay.
  • The patient was given the diagnosis of adult T-cell leukemia/lymphoma based on the initial cutaneous manifestations.
  • The granuloma annulare-like skin lesions in our patient could be considered as a peculiar immunologic hypersensitivity reaction of the host against the tumor cells or persistent human T-cell leukemia virus type I viral antigens.
  • Dermatologists should be aware that this skin condition may be an initial manifestation of adult T-cell leukemia/lymphoma.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19389526.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD5; 0 / DNA, Viral; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


73. Baba M, Okamoto M, Hamasaki T, Horai S, Wang X, Ito Y, Suda Y, Arima N: Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells. J Virol; 2008 Apr;82(8):3843-52
Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells.
  • Human T-lymphotropic virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia (ATL).
  • In this study, we attempted to identify the cell surface molecules that will become suitable targets of antibodies for anti-ATL therapy.
  • The expression levels of approximately 40,000 host genes of three human T-cell lines carrying HTLV-1 genomes were analyzed by oligonucleotide microarray and compared with the expression levels of the genes in an HTLV-1-negative T-cell line.
  • The HTLV-1-carrying T-cell lines used for experiments had totally different expression patterns of viral genome.
  • Among the genes evaluated, the expression levels of 108 genes were found to be enhanced more than 10-fold in all of the T-cell lines examined and 11 of the 108 genes were considered to generate the proteins expressed on the cell surface.
  • In particular, the CD70 gene was upregulated more than 1,000-fold and the enhanced expression of the CD70 molecule was confirmed by laser flow cytometry for various HTLV-1-carrying T-cell lines and primary CD4(+) T cells isolated from acute-type ATL patients.
  • [MeSH-minor] Antigens, Surface / biosynthesis. Cell Line, Tumor. Flow Cytometry. Gene Expression Profiling. Gene Expression Regulation, Viral. Humans. Japan. Leukemia-Lymphoma, Adult T-Cell / virology. Oligonucleotide Array Sequence Analysis. Viral Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):275-81 [15886117.001]
  • [Cites] J Urol. 2005 Jun;173(6):2150-3 [15879877.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5428-38 [15958592.001]
  • [Cites] Retrovirology. 2004;1:39 [15560845.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1794-801 [16043348.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Cancer Metastasis Rev. 2005 Dec;24(4):487-99 [16408158.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2328-37 [16489038.001]
  • [Cites] Eur J Haematol Suppl. 2007 Jan;(67):5-14 [17206982.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1185-92 [17038522.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1245-55 [16909099.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700 [11080812.001]
  • [Cites] Virus Genes. 2001 Jun;22(3):279-87 [11450946.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1150-9 [11493464.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4484-96 [11494144.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2592-9 [11980654.001]
  • [Cites] Mol Pharmacol. 2002 Jun;61(6):1359-65 [12021397.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3562-71 [12068005.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):304-11 [14686487.001]
  • [Cites] Lancet Oncol. 2004 May;5(5):292-302 [15120666.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5978-88 [15199151.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Virology. 1983 Aug;129(1):51-64 [6412453.001]
  • [Cites] EMBO J. 1984 Jun;3(6):1339-43 [6086318.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Jpn J Cancer Res. 1990 Mar;81(3):225-31 [2161813.001]
  • [Cites] J Virol. 1991 Dec;65(12):6892-9 [1719236.001]
  • [Cites] Br J Haematol. 1991 Oct;79(2):263-70 [1958484.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Virol. 1996 May;70(5):3258-63 [8627808.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1645-52 [8622884.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S69-75 [8797707.001]
  • [Cites] J Histochem Cytochem. 1997 Apr;45(4):515-25 [9111230.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):3087-95 [9743375.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1341-9 [10022816.001]
  • [Cites] Clin Immunol. 1999 Nov;93(2):114-23 [10527687.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):129-38 [15671537.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Apr;21(4):273-84 [15943569.001]
  • (PMID = 18256142.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD70; 0 / Antigens, Surface; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2292990
  •  go-up   go-down


74. Kannagi M: Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia. Int J Hematol; 2007 Aug;86(2):113-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.
  • Host T-cell responses to human T-cell leukemia virus type I (HTLV-I) control the expansion of HTLV-I-infected cells and are determinants of the equilibrium proviral load in vivo.
  • Insufficient T-cell responses are regarded as an immunologic risk factor for adult T-cell leukemia (ATL) because they allow increased proviral loads, which represent an epidemiologic risk factor for ATL.
  • Tax-specific CTL responses are strongly activated after hematopoietic stem cell transplantation in some ATL patients in long-term remission, indicating that HTLV-I Tax is expressed in vivo rather than being silent, and that the donor-derived T-cell system can recognize it.
  • [MeSH-major] Human T-lymphotropic virus 1 / immunology. Immunity. Leukemia-Lymphoma, Adult T-Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875523.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


75. Ratner L, Grant C, Zimmerman B, Fritz J, Weil G, Denes A, Suresh R, Campbell N, Jacobson S, Lairmore M: Effect of treatment of Strongyloides infection on HTLV-1 expression in a patient with adult T-cell leukemia. Am J Hematol; 2007 Oct;82(10):929-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of treatment of Strongyloides infection on HTLV-1 expression in a patient with adult T-cell leukemia.
  • Human T-cell leukemia virus type 1 (HTLV-1) is associated with adult T-cell leukemia-lymphoma (ATLL) in about 5% of infected individuals.
  • This case provides support for the hypothesis that Strongyloides is a cofactor for ATLL via T-cell stimulation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 2003 Feb;77(2):164-70 [12627852.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2466-75 [11971181.001]
  • [Cites] Blood. 2002 Jan 1;99(1):88-94 [11756157.001]
  • [Cites] Am J Trop Med Hyg. 2006 Feb;74(2):246-9 [16474078.001]
  • [Cites] J Infect Dis. 2001 Jan 15;183(2):197-205 [11120926.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4954-60 [11042682.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2000 Sep-Oct;95(5):711-2 [10998221.001]
  • [Cites] Adv Cancer Res. 2003;89:69-132 [14587871.001]
  • [Cites] Clin Microbiol Rev. 2004 Jan;17(1):208-17 [14726461.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):4966-74 [15107832.001]
  • [Cites] Adv Cancer Res. 1989;53:33-72 [2552758.001]
  • [Cites] Clin Exp Immunol. 1990 Aug;81(2):207-11 [2143707.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Am J Med. 1992 Feb;92(2):202-8 [1543206.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):771-4 [7917938.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Parasite Immunol. 2004 Nov-Dec;26(11-12):487-97 [15771684.001]
  • [Cites] J Infect Dis. 2005 Feb 15;191(4):612-8 [15655786.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):394-402 [10096585.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):81-7 [8980372.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6 [8680890.001]
  • [Cites] J Infect Chemother. 2004 Dec;10(6):348-51 [15614460.001]
  • (PMID = 17617788.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100730-069003; United States / NCI NIH HHS / CA / CA100730-05; United States / NCI NIH HHS / CA / CA63417; United States / NCI NIH HHS / CA / CA10073; United States / NCI NIH HHS / CA / R01 CA063417; United States / NCI NIH HHS / CA / P01 CA100730-05; United States / NCI NIH HHS / CA / R01 CA105218; United States / NCI NIH HHS / CA / CA100730-069003; United States / NCI NIH HHS / CA / CA105218
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthelmintics; 0 / DNA, Viral; 0 / RNA, Viral; 70288-86-7 / Ivermectin
  • [Other-IDs] NLM/ NIHMS94116; NLM/ PMC2652703
  •  go-up   go-down


76. Matsunaga T, Murase K, Yoshida M, Fujimi A, Iyama S, Kuribayashi K, Sato T, Kogawa K, Hirayama Y, Sakamaki S, Kohda K, Niitsu Y: Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol; 2005 Aug;79(4):294-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma.
  • We report a patient with adult T-cell lymphoma who developed acute myeloid leukemia (AML) after allogeneic cord blood transplantation (CBT).
  • Although 25 cases of donor cell leukemia (DCL) occurring after allogeneic bone marrow transplantation have previously been reported, there have been no reports of DCL after CBT.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Leukemia, Myeloid / etiology. Lymphoma, T-Cell / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Acute Disease. Chromosomes, Human, X / genetics. Chromosomes, Human, Y / genetics. Fatal Outcome. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Tandem Repeat Sequences. Tissue Donors. Transplantation Chimera. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16044441.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Parrula C, Zimmerman B, Nadella P, Shu S, Rosol T, Fernandez S, Lairmore M, Niewiesk S: Expression of tumor invasion factors determines systemic engraftment and induction of humoral hypercalcemia in a mouse model of adult T-cell leukemia. Vet Pathol; 2009 Sep;46(5):1003-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tumor invasion factors determines systemic engraftment and induction of humoral hypercalcemia in a mouse model of adult T-cell leukemia.
  • Infection with human T-cell leukemia virus type 1 (HTLV-1) leads sometimes to the development of adult T-cell lymphoma/leukemia (ATL), which is invariably fatal and often associated with humoral hypercalcemia of malignancy.
  • The transformation of infected CD4 T cells and the pathogenesis of leukemia have been studied with great limitation in tissue culture and patients.
  • In mice, inoculation of HTLV-1 cell lines mostly leads to development of localized lymphomas.
  • To develop an ATL animal model with leukemic spread of ATL cells, mouse strains with different well-defined immune deficiencies were inoculated intraperitoneally with different HTLV-1-infected cell lines (ACH.2, C8166, MT-2, MET-1).
  • Inoculation of MET-1 cells into NOD/SCID mice provided the best model system for slowly developing T-cell leukemia with multiple organ involvement.
  • In contrast to the other cell lines that did not spread systemically, MET-1 expressed both the adhesion molecules CD11a (LFA-1alpha) and CD49d (VLA-4alpha) and produced or induced expression of matrix metalloproteinases 1, 2, 3, and 9, thus underlining the importance of these molecules in the spread of adult T-cell leukemia cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jun;105(12):1697-710 [10862785.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] J Infect Dis. 2006 Dec 1;194(11):1565-9 [17083041.001]
  • [Cites] Ann N Y Acad Sci. 2006 Apr;1068:100-9 [16831910.001]
  • [Cites] J Cell Physiol. 2006 Apr;207(1):244-50 [16402377.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6005-15 [16155607.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] J Virol. 1999 Nov;73(11):9642-9 [10516077.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4747-51 [9616173.001]
  • [Cites] Blood. 1998 May 15;91(10):3909-19 [9573029.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1991-2003 [8952534.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6977-84 [11156399.001]
  • [Cites] J Hum Genet. 2001;46(5):267-72 [11355017.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Blood. 2002 Jan 15;99(2):634-40 [11781248.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1341-9 [11830485.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):561-7 [12007504.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):4732-8 [12391181.001]
  • [Cites] J Virol. 2003 May;77(9):5286-94 [12692230.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):304-11 [14686487.001]
  • [Cites] Lab Invest. 2004 Feb;84(2):263-6 [14688803.001]
  • [Cites] J Pathol. 2004 Mar;202(3):341-51 [14991900.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2039-46 [15026341.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1105-11 [15176993.001]
  • [Cites] Trends Microbiol. 2004 Jul;12(7):346-52 [15223062.001]
  • [Cites] Am J Clin Pathol. 1981 Feb;75(2):149-55 [6970519.001]
  • [Cites] Science. 1982 Aug 20;217(4561):737-9 [6980467.001]
  • [Cites] Virology. 1983 Aug;129(1):51-64 [6412453.001]
  • [Cites] EMBO J. 1984 Jun;3(6):1339-43 [6086318.001]
  • [Cites] Acta Pathol Jpn. 1985 Mar;35(2):437-48 [3875211.001]
  • [Cites] Cancer. 1987 Mar 15;59(6):1187-91 [2880656.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3849-52 [2544261.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [2787512.001]
  • [Cites] Ann Intern Med. 1989 Sep 15;111(6):484-8 [2549824.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Virology. 1993 Sep;196(1):15-24 [8356792.001]
  • [Cites] APMIS. 1995 May;103(5):345-53 [7654359.001]
  • (PMID = 19429977.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100730-07; United States / NCI NIH HHS / CA / CA100730-07S19003; United States / NCI NIH HHS / CA / P01 CA100730-07S19003; United States / NCI NIH HHS / CA / CA100730-07; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11a; 0 / Bsg protein, mouse; 0 / Parathyroid Hormone-Related Protein; 0 / RANK Ligand; 0 / Receptors, Chemokine; 0 / Tnfsf11 protein, mouse; 0 / macrophage inflammatory protein 1alpha receptor; 136894-56-9 / Antigens, CD147; 143198-26-9 / Integrin alpha4; 63231-63-0 / RNA; EC 3.4.24.- / Mmp9 protein, mouse; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS175834; NLM/ PMC2852243
  •  go-up   go-down


78. Liu MM, Furusato E, Cao X, Shen D, Chan CC: Ocular manifestations and pathology of adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus type 1. Rare Tumors; 2010;2(4):e63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular manifestations and pathology of adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus type 1.
  • The human T-cell lymphotropic virus type 1 (HTLV-1), endemic in defined geographical areas around the world, is recognized as the etiologic agent of adult T-cell leukemia/lymphoma (ATL), or HTLV-1.
  • ATL is a rare adult onset T-cell malignancy that is characterized by the presence of ATL flower cells with T-cell markers, HTLV-1 antibodies in the serum, and monoclonal integration of HTLV-1 provirus in affected cells.
  • We also report for the first time a case of a 34-year-old male with systemic ATL and prominent atypical lymphoid cell infiltration in the choroid.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 2001 Mar;131(3):309-13 [11239862.001]
  • [Cites] Am J Ophthalmol. 2001 Mar;131(3):381-3 [11239876.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1717-22 [12208722.001]
  • [Cites] Am J Ophthalmol. 2002 Oct;134(4):616-8 [12383828.001]
  • [Cites] Jpn J Ophthalmol. 2003 Nov-Dec;47(6):599-602 [14636852.001]
  • [Cites] Am J Ophthalmol. 1992 Aug 15;114(2):123-9 [1642286.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Clin Microbiol Rev. 2010 Jul;23(3):577-89 [20610824.001]
  • [Cites] Ophthalmology. 1988 Jan;95(1):110-5 [2893999.001]
  • [Cites] Am J Surg Pathol. 1984 Apr;8(4):263-75 [6324600.001]
  • [Cites] Doc Ophthalmol. 1993;83(4):255-60 [8223094.001]
  • [Cites] Ophthalmology. 1993 Dec;100(12):1794-9 [8259276.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):743-4 [8280693.001]
  • [Cites] AIDS Res Hum Retroviruses. 1993 May;9(5):381-6 [8318266.001]
  • [Cites] Jpn J Ophthalmol. 2005 Jan-Feb;49(1):41-5 [15692773.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):327-9 [16086963.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Microsc Res Tech. 2005 Nov;68(3-4):176-96 [16276549.001]
  • [Cites] Br J Ophthalmol. 2006 Sep;90(9):1204-6 [16929066.001]
  • [Cites] Lancet Infect Dis. 2007 Apr;7(4):266-81 [17376384.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):133-40 [17387298.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):453-9 [19064971.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] J Neuroophthalmol. 1994 Jun;14(2):81-3 [7951932.001]
  • [Cites] Arch Ophthalmol. 1994 Jul;112(7):954-9 [8031276.001]
  • [Cites] J Med Virol. 2010 Apr;82(4):668-74 [20166187.001]
  • [Cites] Jpn J Ophthalmol. 1989;33(1):1-12 [2733251.001]
  • [Cites] Ann Hematol. 1997 Apr;74(4):163-8 [9174543.001]
  • (PMID = 21234255.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / T32 EY007143; United States / Intramural NIH HHS / / ZIA EY000222-25
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019598
  • [Keywords] NOTNLM ; adult T-cell leukemia/lymphoma / eye. / human T-lymphotrophic virus type 1 / pathology
  •  go-up   go-down


79. Liu TY, Chen CY, Tien HF, Lin CW: Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology; 2009 Jan;54(2):214-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma.
  • AIMS: Loss of CD7 is characteristic of adult T-cell lymphoma/leukaemia (ATLL).
  • [MeSH-major] Antigens, CD7 / metabolism. Galectin 3 / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Apoptosis. Cells, Cultured. Chromosome Aberrations. Down-Regulation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207946.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD7; 0 / Galectin 3
  •  go-up   go-down


80. Sanda T, Asamitsu K, Ogura H, Iida S, Utsunomiya A, Ueda R, Okamoto T: Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor. Leukemia; 2006 Apr;20(4):590-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor.
  • NF-kappaB is constitutively activated in adult T-cell leukemia (ATL) and is considered responsible for cell growth and prevention of cell death.
  • In this study, we demonstrate that NF-kappaB is constitutively activated in various HTLV-1-infected T-cell lines and ATL-derived cell lines irrespectively of Tax expression as evidenced by the phosphorylation of IkappaBalpha and p65 subunit of NF-kappaB, activation of NF-kappaB DNA binding, and upregulation of various target genes including bcl-xL, bcl-2, XIAP, c-IAP1, survivin, cyclinD1, ICAM-1 and VCAM-1.
  • The effects of a novel IkappaB kinase (IKK) inhibitor, 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile (ACHP), were examined on cell growth of these cell lines and fresh ATL leukemic cells.
  • We found that ACHP could inhibit the phosphorylation of IkappaBalpha and p65, as well as NF-kappaB DNA-binding, associated with downregulation of the NF-kappaB target genes and induce cell growth arrest and apoptosis in these cells.
  • When Tax-active and Tax-inactive cell lines were compared, ACHP could preferentially inhibit cell growth of Tax-active cells.
  • These findings indicate that ACHP and its derivatives are effective in inducing ATL cell death and thus feasible candidates for the treatment of ATL.
  • [MeSH-major] Enzyme Inhibitors / pharmacology. I-kappa B Kinase / antagonists & inhibitors. Leukemia-Lymphoma, Adult T-Cell / metabolism. Nicotinic Acids / pharmacology. Nitriles / pharmacology. T-Lymphocytes / drug effects
  • [MeSH-minor] Apoptosis / drug effects. Binding Sites. Cell Cycle / drug effects. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. DNA / metabolism. Drug Screening Assays, Antitumor. Enzyme Activation / drug effects. Enzyme Activation / genetics. Enzyme Activation / physiology. Gene Expression Regulation, Enzymologic / drug effects. Human T-lymphotropic virus 1 / metabolism. Humans. In Vitro Techniques. Phosphorylation. Protein Subunits / antagonists & inhibitors. Protein Subunits / genetics. Protein Subunits / metabolism. Structure-Activity Relationship. Transcription Factor RelA / antagonists & inhibitors. Transcription Factor RelA / genetics. Transcription Factor RelA / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16453001.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-piperidin-4-yl nicotinonitrile; 0 / Enzyme Inhibitors; 0 / Nicotinic Acids; 0 / Nitriles; 0 / Protein Subunits; 0 / Transcription Factor RelA; 9007-49-2 / DNA; EC 2.7.11.10 / I-kappa B Kinase
  •  go-up   go-down


81. Idutsu K, Abe Y, Otonari J, Tachikawa Y, Ohtsuka R, Choi I, Muta K, Takayanagi R: [Human herpesvirus 6 encephalitis in a patient with adult T-cell leukemia/lymphoma]. Rinsho Ketsueki; 2007 Aug;48(8):664-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human herpesvirus 6 encephalitis in a patient with adult T-cell leukemia/lymphoma].
  • We describe a 37-year-old woman with the acute type of adult T-cell leukemia/lymphoma who developed HHV-6 encephalitis before chemotherapy.
  • [MeSH-major] Encephalitis, Herpes Simplex / complications. Herpesvirus 6, Human. Leukemia-Lymphoma, Adult T-Cell / complications. Opportunistic Infections / complications. Roseolovirus Infections / complications
  • [MeSH-minor] Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867305.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Chiou CC, Wang PN, Yang LC, Kuo TT, Hong HS: Disseminated xanthogranulomas associated with adult T-cell leukaemia/lymphoma: a case report and review the association of haematologic malignancies. J Eur Acad Dermatol Venereol; 2007 Apr;21(4):532-5
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated xanthogranulomas associated with adult T-cell leukaemia/lymphoma: a case report and review the association of haematologic malignancies.
  • A 68-year-old woman with adult T-cell leukaemia/lymphoma (ATLL) gradually developed disseminated XGs over the 3 years since disease onset.
  • [MeSH-major] Granuloma / etiology. Leukemia-Lymphoma, Adult T-Cell / complications. Skin Diseases / etiology. Xanthomatosis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373983.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 23
  •  go-up   go-down


83. Salcedo-Cifuentes M, Cabrera J, Cuesta-Astroz Y, Carrasca E, Eizuru Y, Domínguez MC, Sánchez A, García-Vallejo F: [Clonal expansion and genomic characterization of the human T-cell lymphotropic virus type I during the integration process in adult T-cell leukemia/lymphoma]. Biomedica; 2009 Jun;29(2):218-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clonal expansion and genomic characterization of the human T-cell lymphotropic virus type I during the integration process in adult T-cell leukemia/lymphoma].
  • INTRODUCTION: Although the integration of human T-cell lymphotropic virus type I into the T-cells is not a random process, the mechanistic details are not understood.
  • OBJECTIVES: The characteristics of the flanking host chromatin were evaluated at the integration sites in adult T-cell leukaemia/lymphoma (ATLL) patients infected with the virus.
  • MATERIALS AND METHODS: From seven leukemic Colombian patients positive for the human T-cell lymphotropic virus type I (HTLV-I), lymphocyte DNA samples were extracted and amplified by inverse polymerase chain reaction (IPCR).
  • RESULTS: The clonal expansion of cell clones was predominantly oligoclonal.
  • Viral DNA integration tended to favor exons of genes that replicated early, controlled the cell cycle, or were involved in signal transduction.
  • CONCLUSIONS: The results indicated that HTLV-I integration was preferentially directed towards genomic environments with high C:G content, and toward genes that replicate early, regulate cell cycle or involved with signal transduction.
  • [MeSH-major] Genome, Viral. Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / virology. Proviruses / genetics. T-Lymphocytes / virology. Virus Integration / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Base Composition. Cell Transformation, Viral / genetics. Child. Child, Preschool. Clone Cells / virology. DNA Replication / genetics. DNA, Neoplasm / genetics. DNA, Viral / genetics. Female. Genes, cdc. Genes, pX. Humans. Male. Middle Aged. Sequence Alignment. Sequence Analysis, DNA. Sequence Homology, Nucleic Acid. Signal Transduction / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20128347.001).
  • [ISSN] 0120-4157
  • [Journal-full-title] Biomédica : revista del Instituto Nacional de Salud
  • [ISO-abbreviation] Biomedica
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Colombia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


84. Wang J, Hasui K, Utsunomiya A, Jia X, Matsuyama T, Murata F: Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL. J Clin Exp Hematop; 2008 Apr;48(1):1-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL.
  • Proliferation, apoptosis and p53 protein expression in adult T-cell leukemia (ATL) cells were investigated.
  • Twenty peripheral blood tissue specimens (PBTS) comprising 7 cases of acute type ATL, 7 cases of chronic type ATL and 6 other leukemias were examined by means of antigen retrieval and the polymer method employing anti-Ki67 antigen (MIB-1), anti-cleaved caspase-3, anti-single stranded DNA and three kinds of anti-p53 protein antibodies including DO7.
  • Most acute and chronic cases of ATL included more than 10% MIB-1-positive proliferating leukemia cells and more than 1% cleaved caspase-3-positive apoptotic cells.
  • Some cells which were positive for both MIB-1 and anti-cleaved caspase-3 antibody were observed in acute type ATL.
  • Nuclear deposition of p53 protein labeled by DO7 was often found in acute type (p < 0.05).
  • Within the medium-sized population of ATL cell nuclei, DO7-positive ATL cells had a smaller nuclear area factor (long axis x short axis) than DO7-negative ATL cells.
  • A few proliferating ATL cells entered apoptosis, and the appearance of a subclone of ATL cells with nuclear deposition of p53 protein labeled by DO7 characterized acute type.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Caspase 3 / biosynthesis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434687.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


85. Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuji K, Hara M, Takanashi M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, Kato S, Sakamaki H, Morishima Y, Okamura J, Ichinohe T, Uchiyama T: Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood; 2010 Aug 26;116(8):1369-76
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used as a curative option for adult T-cell leukemia (ATL), an intractable mature T-cell neoplasm causally linked with human T-cell leukemia virus type I (HTLV-I).
  • [MeSH-major] Graft vs Leukemia Effect / immunology. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Disease Progression. Female. Follow-Up Studies. Graft Survival. Human T-lymphotropic virus 1 / metabolism. Human T-lymphotropic virus 1 / pathogenicity. Humans. Japan / epidemiology. Male. Middle Aged. Retrospective Studies. Survival Rate. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479287.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


86. Nadella MV, Dirksen WP, Nadella KS, Shu S, Cheng AS, Morgenstern JA, Richard V, Fernandez SA, Huang TH, Guttridge D, Rosol TJ: Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia; 2007 Aug;21(8):1752-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma.
  • Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy (HHM) that occurs in the majority of patients with adult T-cell leukemia/lymphoma (ATLL) due to human T-cell lymphotropic virus type-1 (HTLV-1) infection.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Sep;71(9):6277-8 [9261343.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33132-9 [9407099.001]
  • [Cites] Immunol Today. 1998 Feb;19(2):80-8 [9509763.001]
  • [Cites] Annu Rev Physiol. 1998;60:431-60 [9558472.001]
  • [Cites] J Bone Miner Res. 1999 Mar;14(3):406-14 [10027905.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Virology. 1996 Dec 15;226(2):167-75 [8955035.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3744-50 [8670878.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1035-45 [8704212.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1342-8 [8657107.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1349-57 [8625910.001]
  • [Cites] Eur J Haematol. 1996 Jan-Feb;56(1-2):116-7 [8599987.001]
  • [Cites] Miner Electrolyte Metab. 1995;21(1-3):166-70 [7565442.001]
  • [Cites] J Biol Chem. 1995 Feb 17;270(7):3123-31 [7852394.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] Genes Dev. 1993 Jul;7(7B):1354-63 [8330739.001]
  • [Cites] Mol Cell Biol. 1999 Aug;19(8):5785-99 [10409765.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1175-83 [15889157.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5952-64 [16155602.001]
  • [Cites] Mol Cell. 2006 Feb 3;21(3):393-404 [16455494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5899-904 [16595631.001]
  • [Cites] Immunol Res. 2006;34(1):1-12 [16720895.001]
  • [Cites] J Virol. 1993 Jul;67(7):4205-13 [8510222.001]
  • [Cites] Mol Endocrinol. 1993 Feb;7(2):273-82 [8469240.001]
  • [Cites] Cell. 1993 Mar 12;72(5):729-39 [8453667.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;182:421-4 [1490380.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Dec 15;189(2):938-43 [1472066.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1642-52 [1280327.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):339-42 [1406939.001]
  • [Cites] Mol Endocrinol. 1990 Jun;4(6):851-8 [2233743.001]
  • [Cites] Gene. 1989 Apr 15;77(1):95-105 [2744490.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):556-63 [3043221.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] Cell. 2004 Aug 20;118(4):453-64 [15315758.001]
  • [Cites] Neoplasia. 2004 May-Jun;6(3):266-78 [15153339.001]
  • [Cites] EMBO J. 1997 Jun 16;16(12):3609-20 [9218802.001]
  • [Cites] J Neurochem. 2000 Oct;75(4):1377-89 [10987817.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6977-84 [11156399.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45380-6 [11567031.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9722-32 [12509424.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2789-96 [12456498.001]
  • (PMID = 17554373.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCRR NIH HHS / RR / RR07073; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / T32 RR007073; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; None / None / / P01 CA100730-01; United States / NCI NIH HHS / CA / P01 CA100730-01; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; EC 2.3.1.28 / Chloramphenicol O-Acetyltransferase
  • [Other-IDs] NLM/ NIHMS94363; NLM/ PMC2676796
  •  go-up   go-down


87. Yamasaki M, Fujita S, Ishiyama E, Mukai A, Madhyastha H, Sakakibara Y, Suiko M, Hatakeyama K, Nemoto T, Morishita K, Kataoka H, Tsubouchi H, Nishiyama K: Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo. Cancer Sci; 2007 Nov;98(11):1740-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo.
  • Adult T-cell leukemia occurs in human T-lymphotropic virus type I-infected individuals and is endemic to the south-western area of Kyushu in Japan.
  • In this communication, we examined the effect of soy isoflavones on the growth of adult T-cell leukemia cells in vitro and in vivo.
  • Among the isoflavones studied, genistein had the highest growth-inhibitory effect; however, genistein did not exert an apparent growth-inhibitory effect on Jurkat and Molt-4 cells, which were non-adult T-cell leukemia cells.
  • The in vivo studies demonstrated that soy-derived isoflavones significantly inhibit ED-40515 cell growth and infiltration into various organs in non-obese diabetic severe combined-immunodeficiency common gamma-chain knockout mice.
  • Taken together, it is evident that soy isoflavones might serve as a promising compound for the treatment of adult T-cell leukemia.
  • [MeSH-major] Isoflavones / pharmacology. Isoflavones / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Soybeans
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Genistein / pharmacology. Humans. Jurkat Cells. Mice. Mice, Knockout. Mice, SCID. Transplantation, Heterologous

  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727682.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoflavones; 6287WC5J2L / daidzein; 92M5F28TVF / glycitein; DH2M523P0H / Genistein
  •  go-up   go-down


88. Muraoka S, Ito Y, Kamimura M, Baba M, Arima N, Suda Y, Hashiguchi S, Torikai M, Nakashima T, Sugimura K: Effective induction of cell death on adult T-cell leukaemia cells by HLA-DRbeta-specific small antibody fragment isolated from human antibody phage library. J Biochem; 2009 Jun;145(6):799-810

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective induction of cell death on adult T-cell leukaemia cells by HLA-DRbeta-specific small antibody fragment isolated from human antibody phage library.
  • By a biopanning method using cell sorter, we quickly isolated an antibody phage clone (S1T-A3) specific to human T-lymphotropic virus type 1-carrying T-cell line S1T from a human single chain Fv (scFv) antibody phage library.
  • This scFv antibody bound to HTLV-1-carrying T-cell lines including MT-2, MT-4 and M8166 other than S1T, but not to non-HTLV-1-carrying T-cell lymphomas such as Jurkat and MOLT4 cells.
  • Interestingly, this antibody induced the cell death on S1T cells very quickly (< 30 min).
  • The cell death was induced only in dimmer form of scFv (diabody) and at 15-fold lower concentration than that of a fusion protein of scFv and human IgG Fc [(scFv)(2)-Fc] or anti HLA-DR mouse whole antibody L243.
  • Thus, S1T-A3 diabody is a small antibody fragment with agonistic activity to induce cell death through HLA-DR.
  • This is the first report elucidating that diabody specific to HLA-DR is effective to induce the cell death in T-cell malignancy especially adult T-cell leukaemic cell line.
  • [MeSH-major] Apoptosis / drug effects. HLA-DR Antigens / immunology. Immunoglobulin Fragments / immunology. Immunoglobulin Fragments / pharmacology. Leukemia, T-Cell / pathology. Peptide Library
  • [MeSH-minor] Animals. Cell Line. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Humans. Mass Spectrometry. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19270058.001).
  • [ISSN] 1756-2651
  • [Journal-full-title] Journal of biochemistry
  • [ISO-abbreviation] J. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / Immunoglobulin Fragments; 0 / Peptide Library
  •  go-up   go-down


89. Callens C, Moura IC, Lepelletier Y, Coulon S, Renand A, Dussiot M, Ghez D, Benhamou M, Monteiro RC, Bazarbachi A, Hermine O: Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia; 2008 Jan;22(1):42-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody.
  • HTLV-I is an endemic retrovirus responsible for the adult T-cell leukemia/lymphoma (ATLL).
  • Monoclonal antibodies to target cell differentiation markers on ATLL cells have already been proposed as therapeutic agents.
  • However, in clinical trials acute forms of ATLL were resistant to these immunotherapies.
  • In HTLV-I-infected cells, A24 targets and induces apoptosis of both chronic and acute ATLL forms, independent of antibody aggregation, antibody-dependent cellular cytotoxicity and/or complement addition.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia, T-Cell / therapy. Receptors, Transferrin / immunology
  • [MeSH-minor] Adult. Humans. Immunotherapy. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898788.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Receptors, Transferrin
  • [Number-of-references] 53
  •  go-up   go-down


90. Harakeh S, Diab-Assaf M, Khalife JC, Abu-el-Ardat KA, Baydoun E, Niedzwiecki A, El-Sabban ME, Rath M: Ascorbic acid induces apoptosis in adult T-cell leukemia. Anticancer Res; 2007 Jan-Feb;27(1A):289-98
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ascorbic acid induces apoptosis in adult T-cell leukemia.
  • BACKGROUND: Adult T-cell leukemia (ATL) is an acute malignancy of activated T-cells caused by the human T-cell lymphotrophic virus type-1 (HTLV-1).
  • The effect of AA on apoptosis and proliferation was evaluated by cell cycle analysis.
  • The role of p53, p21 Bax and Bcl-2a on cell cycle modulation and apoptosis was also assessed.
  • [MeSH-major] Apoptosis / drug effects. Ascorbic Acid / pharmacology. HTLV-I Infections / drug therapy. Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Cell Cycle / drug effects. Cell Growth Processes / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Humans. Jurkat Cells. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Transforming Growth Factors / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. bcl-2-Associated X Protein / biosynthesis

  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352246.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 76057-06-2 / Transforming Growth Factors; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


91. Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y, Matsubara K, Qi X, Saitoh T, Imoto I, Inazawa J, Utsunomiya A, Watanabe T, Masuda T, Yamamoto N, Yamaoka S: Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood; 2008 May 15;111(10):5118-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells.
  • The nuclear factor-kappaB (NF-kappaB) transcription factors play important roles in cancer development by preventing apoptosis and facilitating the tumor cell growth.
  • In our current study, we now report that NF-kappaB-inducing kinase (NIK) is overexpressed at the pretranslational level in adult T-cell leukemia (ATL) and Hodgkin Reed-Sternberg cells (H-RS) that do not express viral regulatory proteins.
  • The overexpression of NIK causes cell transformation in rat fibroblasts, which is abolished by a super-repressor form of IkappaBalpha.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Hodgkin Disease / etiology. Leukemia-Lymphoma, Adult T-Cell / etiology. NF-kappa B / antagonists & inhibitors. Protein-Serine-Threonine Kinases / genetics. Protein-Serine-Threonine Kinases / physiology
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic. Mice. RNA, Small Interfering / pharmacology. Rats. Reed-Sternberg Cells / enzymology. Reed-Sternberg Cells / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18305221.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / RNA, Small Interfering; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.25 / NF-kappa B kinase
  •  go-up   go-down


92. Masuda M, Maruyama T, Ohta T, Ito A, Hayashi T, Tsukasaki K, Kamihira S, Yamaoka S, Hoshino H, Yoshida T, Watanabe T, Stanbridge EJ, Murakami Y: CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells. J Biol Chem; 2010 May 14;285(20):15511-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells.
  • CADM1 encodes a multifunctional immunoglobulin-like cell adhesion molecule whose cytoplasmic domain contains a type II PSD95/Dlg/ZO-1 (PDZ)-binding motif (BM) for associating with other intracellular proteins.
  • Although CADM1 lacks expression in T lymphocytes of healthy individuals, it is overexpressed in adult T-cell leukemia-lymphoma (ATL) cells.
  • In this study, we demonstrated that the cytoplasmic domain of CADM1 directly interacted with the PDZ domain of Tiam1 and induced formation of lamellipodia through Rac activation in HTLV-I-transformed cell lines as well as ATL cell lines.
  • [MeSH-major] Guanine Nucleotide Exchange Factors / metabolism. Human T-lymphotropic virus 1 / pathogenicity. Immunoglobulins / metabolism. Leukemia, T-Cell / pathology. Membrane Proteins / metabolism. Neoplasm Invasiveness. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Cell Adhesion Molecules. Cell Line, Tumor. Humans. Immunohistochemistry. Microscopy, Confocal. Molecular Sequence Data. Protein Binding. RNA Interference. RNA, Small Interfering. Sequence Homology, Amino Acid

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Dec 1;62(2):139-46 [10610705.001]
  • [Cites] Retrovirology. 2006;3:71 [17042961.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):427-30 [11279526.001]
  • [Cites] Annu Rev Neurosci. 2001;24:1-29 [11283303.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Mol Reprod Dev. 2001 Oct;60(2):158-64 [11553913.001]
  • [Cites] Neuroreport. 2001 Oct 29;12(15):3217-21 [11711859.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):867-71 [12075356.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):31014-9 [12050160.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1525-31 [12202822.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5129-33 [12234973.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2601-8 [12456501.001]
  • [Cites] Biol Reprod. 2003 May;68(5):1755-63 [12606335.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):11-6 [12829230.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Lab Invest. 2003 Aug;83(8):1175-83 [12920246.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35421-7 [12826663.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6160-5 [13679854.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):583-9 [14519393.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7979-85 [14633730.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):495-508 [14530271.001]
  • [Cites] Cell. 2004 Jan 23;116(2):167-79 [14744429.001]
  • [Cites] Trends Cell Biol. 2007 Jan;17(1):36-43 [17126549.001]
  • [Cites] Hepatology. 2007 Mar;45(3):684-94 [17326163.001]
  • [Cites] J Cell Biol. 2007 Mar 12;176(6):863-75 [17353362.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13864-74 [17339315.001]
  • [Cites] Rev Med Virol. 2007 Sep-Oct;17(5):301-11 [17621367.001]
  • [Cites] J Neurosci. 2007 Nov 14;27(46):12516-30 [18003830.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] J Virol. 2008 Dec;82(23):11958-63 [18922876.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):21-32 [14999151.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Oct;80(19):6061-5 [6193528.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Cell. 1994 May 20;77(4):537-49 [7999144.001]
  • [Cites] Nature. 1995 May 25;375(6529):338-40 [7753201.001]
  • [Cites] Science. 1997 Jan 3;275(5296):73-7 [8974395.001]
  • [Cites] J Cell Biol. 1997 Apr 21;137(2):387-98 [9128250.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):4066-74 [9670021.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):501-11 [9927410.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):185-90 [15621800.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6934-42 [15905536.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21955-64 [15781451.001]
  • [Cites] Retrovirology. 2005;2:27 [15854229.001]
  • [Cites] Blood. 2005 Aug 1;106(3):779-86 [15811952.001]
  • [Cites] Int Immunol. 2005 Sep;17(9):1227-37 [16091383.001]
  • [Cites] Cancer Sci. 2005 Sep;96(9):543-52 [16128739.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42164-71 [16223734.001]
  • [Cites] Trends Cell Biol. 2006 Oct;16(10):522-9 [16949823.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1139-46 [16952304.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):369-76 [11054665.001]
  • (PMID = 20215110.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / Guanine Nucleotide Exchange Factors; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / TIAM1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2865322
  •  go-up   go-down


93. Hishizawa M, Imada K, Sakai T, Ueda M, Hori T, Uchiyama T: Serological identification of adult T-cell leukaemia-associated antigens. Br J Haematol; 2005 Aug;130(3):382-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serological identification of adult T-cell leukaemia-associated antigens.
  • Adult T-cell leukaemia (ATL) is a peripheral T-cell neoplasm caused by human T-cell leukaemia virus type I (HTLV-I).
  • Among five distinct genes isolated, serine/arginine protein kinase 1 (SRPK1), which has been reported to have a restricted normal tissue distribution, was found to be overexpressed in most acute type ATL samples, but not in chronic type ATL or in normal peripheral blood mononuclear cells by real-time reverse transcription polymerase chain reaction.
  • [MeSH-major] Antigens, Neoplasm / isolation & purification. Leukemia, T-Cell / immunology. Protein-Serine-Threonine Kinases / isolation & purification
  • [MeSH-minor] Adult. Biomarkers / blood. Blotting, Western / methods. Case-Control Studies. Cell Line, Tumor. Human T-lymphotropic virus 1 / immunology. Humans. Male. RNA, Messenger / analysis. Recombinant Proteins. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042687.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / RNA, Messenger; 0 / Recombinant Proteins; EC 2.7.1.- / SRPK1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


94. Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K, Kyushu Hematology Organization for Treatment Study Group (K-HOT): THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol; 2010 May;84(5):391-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
  • The subset analysis showed that T-cell lymphoma had a significantly better response with THP-COP, whereas no such difference was observed in B-cell lymphoma.
  • The aim of this study is to confirm the efficacy of THP-COP in the treatment of T-cell lymphoma.
  • METHODS: We underwent a multicenter phase II study of THP-COP as a first-line treatment for T-cell lymphoma.
  • Seventeen patients had peripheral T-cell lymphoma (PTCL), including nine of PTCL not otherwise specified (PTCL-NOS) and eight of angioimmunoblastic T-cell lymphoma (AITL).
  • Thirty-six patients had adult T-cell leukemia/lymphoma (ATLL), including 20 of acute type and 16 of lymphoma type.
  • CONCLUSION: The efficacy of THP-COP is equivalent to that of CHOP for the first-line therapy in T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Prednisolone / adverse effects. Prednisolone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059527.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


95. Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, Eto T, Hidaka M, Harada M, Choi I, Yamanaka T, Kannagi M, Matsuoka M, Okamura J: Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant; 2008 Jun;14(6):702-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for adult T cell leukemia/lymphoma (ATLL), but shows high mortality.
  • Analysis of combined data from both our current and previous studies disclosed that grade I-II acute GVHD was the only factor that favorably affected OS and PFS.
  • [MeSH-major] Antilymphocyte Serum / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / surgery. Transplantation Conditioning / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489996.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents
  •  go-up   go-down


96. Miura H, Maeda M, Yamamoto N, Yamaoka S: Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells. Exp Cell Res; 2005 Aug 1;308(1):29-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells.
  • We have recently shown constitutive IkappaB kinase (IKK) activation and aberrant p52 expression in adult T cell leukemia (ATL) cells that do not express human T cell leukemia virus type I (HTLV-I) Tax, but the mechanism of IKK activation in these cells has remained unknown.
  • [MeSH-major] Cell Transformation, Viral / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Arsenites / pharmacology. Cell Line, Transformed. Cell Line, Tumor. Cycloheximide / antagonists & inhibitors. Cycloheximide / pharmacology. Enzyme Inhibitors / pharmacology. Human T-lymphotropic virus 1 / physiology. Humans. I-kappa B Kinase. Leupeptins / pharmacology. Proteasome Endopeptidase Complex / metabolism. Protein Synthesis Inhibitors / pharmacology. T-Lymphocytes / drug effects. T-Lymphocytes / metabolism

  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878527.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / Enzyme Inhibitors; 0 / Leupeptins; 0 / Protein Synthesis Inhibitors; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 98600C0908 / Cycloheximide; EC 2.7.1.- / IKBKE protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.10 / CHUK protein, human; EC 2.7.11.10 / I-kappa B Kinase; EC 2.7.11.10 / IKBKB protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex; N5509X556J / arsenite
  •  go-up   go-down


97. Pezeshkpoor F, Yazdanpanah MJ, Shirdel A: Specific cutaneous manifestations in adult T-cell leukemia/lymphoma. Int J Dermatol; 2008 Apr;47(4):359-62
Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific cutaneous manifestations in adult T-cell leukemia/lymphoma.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy which may occur in individuals infected with human T-cell lymphotropic virus type-I (HTLV-I).
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Skin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Iran. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377598.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Sawada S, Ishikawa C, Tanji H, Nakachi S, Senba M, Okudaira T, Uchihara JN, Taira N, Ohshiro K, Yamada Y, Tanaka Y, Uezato H, Ohshima K, Sasai K, Burgering BM, Duc Dodon M, Fujii M, Sunakawa H, Mori N: Overexpression of caveolin-1 in adult T-cell leukemia. Blood; 2010 Mar 18;115(11):2220-30
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of caveolin-1 in adult T-cell leukemia.
  • Adult T-cell leukemia (ATL) is a T-cell malignancy causatively associated with human T-cell leukemia virus type 1 (HTLV-1).
  • To determine the role of caveolin-1 in leukemogenesis, we examined caveolin-1 expression levels in HTLV-1-infected T-cell lines and ATL cells.
  • These cells expressed high levels of caveolin-1 compared with uninfected T-cell lines and normal peripheral blood mononuclear cells (PBMCs).
  • Infection of a human T-cell line, an epithelial cell line, and normal PBMCs with HTLV-1 induced caveolin-1 expression.
  • HTLV-1-infected T-cell lines, and ATL cells are known to be resistant to transforming growth factor beta (TGF-beta)-induced growth inhibition.
  • Caveolin-1 was colocalized with TGF-beta type I receptor in HTLV-1-infected T-cell lines and suppressed TGF-beta signaling.
  • Caveolin-1 knockdown in an HTLV-1-infected T-cell line exhibited susceptibility to TGF-beta.
  • [MeSH-major] Caveolin 1 / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism
  • [MeSH-minor] Adult. Cell Line. Cell Membrane / metabolism. Cell Proliferation. Cyclic AMP Response Element-Binding Protein / metabolism. Gene Expression Regulation, Leukemic. Humans. NF-kappa B / metabolism. Promoter Regions, Genetic / genetics. Protein-Serine-Threonine Kinases / metabolism. Receptors, Transforming Growth Factor beta / metabolism. Signal Transduction. T-Lymphocytes / metabolism. T-Lymphocytes / pathology. T-Lymphocytes / virology. Transcriptional Activation / genetics. Transforming Growth Factor beta / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Blood. 2010 Aug 26;116(8):1386 [20574044.001]
  • (PMID = 20061557.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / Cyclic AMP Response Element-Binding Protein; 0 / NF-kappa B; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


99. Yoshie O: Expression of CCR4 in adult T-cell leukemia. Leuk Lymphoma; 2005 Feb;46(2):185-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CCR4 in adult T-cell leukemia.
  • Adult T-cell leukemia (ATL) is a malignancy of mature T cells that is etiologically associated with human T-cell leukemia virus type 1 (HTLV-1).
  • Besides certain cell adhesion molecules and matrix metalloproteineses, chemokine receptors may play important roles in tissue infiltration of ATL.
  • Since CCR4 is known to be involved in T cell migration into skin, this may in part explain the frequent skin infiltration in ATL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / immunology. Receptors, Chemokine / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621800.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCR4 protein, human; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  • [Number-of-references] 44
  •  go-up   go-down


100. Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, Soares GM, Alcantara LC Jr, Van Dooren S, Galvão-Castro B, Vandamme AM, Van Weyenbergh J: Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol; 2008 Jan;83(1):220-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia.
  • Fas gene mutations, aberrant transcripts, and abundant expression of Fas have been reported in adult T cell leukemia (ATL).
  • The AA group also comprised significantly more aggressive (acute and lymphoma) clinical subtypes [P=0.012; OR=8.40; 95% CI (1.60-44.12)].
  • [MeSH-major] Antigens, CD95 / genetics. Genetic Predisposition to Disease / genetics. Leukemia, T-Cell / genetics. Polymorphism, Single Nucleotide / genetics. Promoter Regions, Genetic / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962369.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / RNA, Messenger; 82115-62-6 / Interferon-gamma
  •  go-up   go-down






Advertisement